

# ANNUAL REPORT

## 2021 – 2022



# AASHKA HOSPITALS LIMITED

<b>Directors</b>	Mr. Bipinchandra D. Shah Mrs. Shreyarathi B. Shah Mr. Parag R. Thaker Mr. Hiteshkumar R. Shah Mr. Umang A. Shah <i>(Appointed w.e.r. October 7, 2022)</i>	Chairman & Managing Director Director Director Independent Director Independent Director
	Mr. Lokesh Khandelwal <i>(Appointed w.e.f. October 7, 2022)</i> Mr. Mayank Agarwal <i>(Appointed w.e.f. October 7, 2022)</i>	Chief Financial Officer Company Secretary
<b>Audit Committee</b>	Mr. Umang A. Shah Mr. Hiteshkumar R. Shah Mrs. Shreyarathi B. Shah	Chairman
<b>Nomination &amp; Remuneration Committee</b>	Mr. Umang A. Shah Mr. Hiteshkumar R. Shah Mrs. Shreyarathi B. Shah	Chairman
<b>Stakeholders Relationship Committee</b>	Mr. Umang A. Shah Mr. Bipinchandra D. Shah Mrs. Shreyarathi B. Shah	Chairman
<b>Statutory Auditors</b>	M/s. Singhi & Co. Chartered Accountants Ahmedabad	
<b>Registered Office</b>	Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar – 382421	
<b>Registrar &amp; Share Transfer Agent</b>	Accurate Securities & Registry Private Limited 203, Shangrila Arcade, Above Samsung Showroom, Nr. Shyamal Cross Road, Satellite, Ahmedabad – 380015 Ph: +91-79-4800-0319   E-mail: <a href="mailto:investors@accuratesecurities.com">investors@accuratesecurities.com</a> Web: <a href="http://www accuratesecurities.com">www accuratesecurities.com</a>	

**Notice of the 10<sup>th</sup> Annual General Meeting of the Company to be held on Friday, April 28, 2023 at 11:30 am at Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar – 382421**

Shareholders intending to require information about the accounts to be explained at the Meeting are requested to inform the Company at least 7 days in advance of the Annual General Meeting

**Aashka Hospitals Ltd.**

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421. Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
www.aashkahospitals.in  
CIN: L85110GJ2012PLC072647



## NOTICE

Notice is hereby given that the 10<sup>th</sup> Annual General Meeting of the Members of **Aashka Hospitals Limited** will be held on Friday, April 28, 2023 at 11:30 a.m. at Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar – 382421 to transact the following business:

### ORDINARY BUSINESSES:

#### 1. Adoption of Financial Statements

To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2022 together with the Board's Report and the Auditor's Report thereon.

#### 2. Re-appointment of a Director

To appoint Director in the place of Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108), who retires by rotation and being eligible, offers himself for re-appointment.

### SPECIAL BUSINESSES:

#### 3. To Appoint Mr. Umang Ashwinbhai Shah (DIN: 09735002) as an Independent Director of the Company

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to the provisions of Section 149, 150, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (“the Act”) and the Rules framed thereunder and pursuant to the recommendations made by the Nomination and Remuneration Committee and by the Board of Directors of the company, Mr. Umang Ashwinbhai Shah (DIN: 09735002), who has been appointed as Additional Independent Director by the Board of Directors of the Company w.e.f. October 7, 2022, and who meets the criteria for independence as provided in Section 149(6) of the Act and the Rules framed thereunder and in respect of whom the Company has received a notice in writing from a member under Section 160(1) of the Act proposing his candidature for the office of Director, be and is hereby appointed as a Non – Executive Independent Director of the Company to hold office for 5 (Five) consecutive years for a term upto October 6, 2027.

**RESOLVED FURTHER THAT** the Board of Directors of the Company, be and is hereby authorized to do all such acts, deeds and things to enter into such agreement(s), deed(s) of amendment(s) or any such document(s), as the Board may, in its absolute discretion, consider necessary, expedient or desirable including power to sub-delegate, in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company.”

**4. To re-appoint Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108) as Chairman and Managing Director**

To consider and, if thought fit, to pass the following resolution as a **Special Resolution:**

“**RESOLVED THAT** pursuant to the provisions under Section 196, 197, 198, Schedule V as applicable and other applicable provisions, if any, of the Companies Act, 2013 (“**the Act**”) and on recommendation of the Nomination and Remuneration Committee, the consent of the members be and is hereby accorded for the payment of remuneration as tabled below or such other remuneration within the maximum permissible remuneration as specified in Schedule V of the Act to Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108), Chairman & Managing Director of the Company w.e.f. September 20, 2023 for the tenure of 3 (three) years:

**Basic Salary:** ₹ 10,00,000/- per month or such higher amount within the limits of Schedule V

**Perquisites & Allowances:**

- a) **House Rent Allowances:** Nil
- b) **Accommodation:** Rent free accommodation with all the equipment’s and appliances, furniture, fixtures and reimbursement of expenses of maintenance, gas, electricity, servants, etc. equivalent to ₹ 2,00,000/- per month
- c) **Personal Accident Insurance:** The Company shall pay / reimburse Personal Accident Insurance Premium
- d) **Medical Reimbursement / Treatment at Company’s Hospitals:** Medical expenses actually incurred shall be reimbursed by the Company or the Treatment shall be given at the Company’s Hospitals with no extra cost to the Chairman & Managing Director and his family.
- e) **Leave Travel Concession:** The Company shall provide leave travel fare for the Chairman & Managing Director and his family once in a year
- f) **Club Fees:** The Company shall reimburse annual fees for a maximum of 2 (two) clubs
- g) **Gratuity:** as per applicable laws
- h) **Other allowances:** The Company shall pay other allowances, scholarship, travel / conveyance, etc. as per the Company Policy

**RESOLVED FURTHER THAT** the overall managerial remuneration payable to Mr. Bipinchandra Dineshbhai Shah may be varied / altered / revised by the Board from time to time on recommendation of the Nomination and Remuneration Committee, which shall be within the maximum permissible limits prescribed under Schedule V of the Act.

**RESOLVED FURTHER THAT** where in any Financial Year during his tenure as Chairman and Managing Director, if the Company has no profits or profits are inadequate, the aforesaid remuneration or remuneration varied / altered / revised by the Board shall be the minimum remuneration to be paid to him.

**RESOLVED FURTHER THAT** any of the Directors and / or the Key Managerial Personnel of the Company, be and is hereby are severally authorized to do all such acts, deeds, matters and things as they may in their absolute discretion deem necessary, proper and desirable and to file necessary e-forms with the concerned Registrar of Company and to do such act, deeds and things to give effect to the aforementioned resolution.”

Registered Office  
Between Sargasan & Reliace Cross Road,  
Sargasan – Gandhinagar, Gandhinagar

By Order of the Board  
For, Aashka Hospitals Limited

Date: 31/03/2023  
Place: Gandhinagar

Bipinchandra Dineshbhai Shah  
Chairman & Managing Director  
DIN: 00934108

**NOTES:**

- (a) The Statement, pursuant to Section 102 of the Companies Act, 2013, as amended ('Act') with respect to Item Nos. 3 & 4, forms part of this Notice. Additional information, pursuant to Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Director seeking appointment / re-appointment at this Annual General Meeting ('Meeting' or 'AGM') is furnished as an annexure to the Notice.
- (b) In accordance with the Ministry of Corporate Affairs ("MCA"), General Circulars Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020, 02/2021 dated January 13, 2021, 21/2021 dated December 14, 2021 and 2/2022 dated May 5, 2022, respectively, ("the MCA Circulars") read with the Securities and exchange Board of India ("SEBI") circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022 ("the SEBI Circular"), the Notice of 10<sup>th</sup> Annual General Meeting ("AGM") is being sent only through electronic mode to those members whose e-mail addresses are registered with the Company / Depositories and to all members whose names appear on the Register of Members / List of Beneficial Owners as on March 31, 2023 as received from the Depositories. The MCA vide the MCA Circulars, has permitted companies to conduct the AGM by sending the Notice and Annual Report in electronic form only. Accordingly, physical copy of this Notice along with the Annual Report will not be sent to the Members for this AGM.
- (c) A member entitled to attend and vote is entitled to appoint a proxy to attend and vote instead of him / herself and proxy need not be a member. The instrument appointing a proxy must be deposited at the Registered Office of the Company not later than 48 hours before the commencement of the meeting.

A person can act as a proxy on behalf of members not exceeding 50 (Fifty) and holding in the aggregate not more than 10 (Ten) per cent of the total share capital of the company carrying voting rights. A member holding more than 10 (Ten) per cent of the total share capital of the company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.

- (d) Corporate Members intending to have their representatives attend the Meeting pursuant to Section 113 of the Act, are requested to send to the Company, a certified copy of the relevant Board Resolution to attend and vote on their behalf at the meeting.
- (e) The Register of Beneficial Owners, Register of Members and Share Transfer Books of

the Company will remain closed from Saturday, April 22, 2023 to Friday, April 28, 2023 (both days inclusive).

- (f) In line with the MCA Circular dated May 5, 2020, the Notice of the AGM along with the Integrated Report & Annual Accounts 2021-22 is being sent only through electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories. The Notice convening the 10<sup>th</sup> AGM has been uploaded on the website of the Company at [www.aashkahospitals.in](http://www.aashkahospitals.in). The Notice is also available on the website of NSDL at [www.evoting.nsdl.com](http://www.evoting.nsdl.com)
- (g) As per the provision of Section 72 of the Act, the facility for making Nomination is available for the members in respect of their shareholding in the Company either in single or with joint names. The members are requested to submit the complete and signed form SH-13 with their Depository Participant (DP) who holds the shares in dematerialized form and those who are holding physical shares shall send the same to the Registrar and Share Transfer Agent – Accurate Securities and Registry Private Limited (the 'RTA').
- (h) Dividends are now taxable in the hands of shareholders hence shareholders are requested to submit form 15G/15H/10F, as the case may be for tax exemption directly on the portal of our RTA i.e. Accurate Securities and Registry Private Limited.
- (i) Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the listed companies to issue securities in dematerialized form only while processing service requests viz. issue of duplicate share certificate; claim from unclaimed suspense account; renewal / exchange of share certificate; endorsement; subdivision / splitting of share certificate; consolidation of the share certificates / folios; transmission and transposition. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialisation, Members are advised to dematerialise the shares held by them in physical form. Members can contact the Company or Accurate Securities and Registry Private Limited, for assistance in this regard. Accordingly, Members are requested to make service request by submitting a duly filled and signed Form ISR – 4, the format of which is available on the RTA website. It may be noted that any service request can be processed only after the Folio is KYC compliant.
- (j) The SEBI has mandated submission of Permanent Account Number (“PAN”) by every participant in securities market. Accordingly, members holding shares in electronic form are requested to submit their PAN to their respective Depository Participants. Members holding shares in physical form can submit their PAN to the Company / Registrar and Share Transfer Agent.
- (k) Members seeking any information or clarifications on the Annual Report are requested to send their queries to the company on [csaashkahospital@gmail.com](mailto:csaashkahospital@gmail.com) or [cs@aashkahospitals.in](mailto:cs@aashkahospitals.in) at least one week prior to the Meeting to enable the Company to compile the information and provide replies at the Meeting.
- (l) Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system will be provided by NSDL.

- (m) Members holding shares in physical form are requested to notify/send the following to the RTA of the Company:
- a. Any change in their mailing address;
  - b. Particulars of their bank account, pan no. & e-mail ids in case the same have not been sent earlier;
  - c. Members who hold shares in physical form in multiple folios in identical names are requested to send the share certificate for consolidation into single folio. Further, please note that Members holding equity shares in electronic form are requested to contact to their DP with whom they are maintaining the demat accounts for updation in address, pan no., e-mail IDs, Bank details, Bank mandate, ECS mandate, etc.
- (n) The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, the Register of Contracts or arrangements in which Directors are interested under Section 189 of the Act will be available for inspection.
- (o) The remote e-voting period commences at 09:00 a.m. IST on Tuesday, April 25, 2023 and ends at 5:00 p.m. IST on Thursday, April 27, 2023. During this period, members of the Company holding shares either in physical form or in dematerialized form, as on Cut-off date of Friday, April 21, 2023 ('Cut-off date'), may cast their vote by remote e-voting. No remote e-voting shall be allowed beyond the aforesaid date and time and the remote e-voting module shall be disabled for voting upon expiry of the aforesaid period. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently
- (p) The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the Friday, April 21, 2023. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. Friday, April 21, 2023, may obtain the login ID and password by sending a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)
- (q) The Board of Directors has appointed Mr. Jay Surti (Mem. No. F11534) partner of M/s. Suthar & Surti, Company Secretaries, as the Scrutinizer to scrutinize the remote e-voting process before and during the AGM in a fair and transparent manner.
- (r) The Scrutinizer shall, immediately after the conclusion of voting at the AGM, count the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least 2 witnesses not in employment of the Company. The Scrutinizer shall submit a consolidated Scrutinizer's Report of the total votes cast in favour of or against, if any, not later than 3 days after the conclusion of the AGM to the Chairman of the Company. The Chairman, or any other person authorised by the Chairman, shall declare the result of the voting forthwith. The result declared along with the consolidated Scrutinizer's Report shall be placed on the Company's website <http://www.aashkahospitals.in> and on the website of NSDL immediately after the result is declared by the Chairman.

**THE INSTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:**

- (i) The voting period begins at 09:00 a.m. IST on Tuesday, April 25, 2023 and ends at 5:00 p.m. IST on Thursday, April 27, 2023. During this period, shareholders of the Company holding shares either in physical form or in dematerialized form, as on the cut-off date Friday, April 21, 2023 may cast their vote electronically. The e-voting module shall be

disabled by NSDL for voting thereafter.

- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode** is given below:

**The instructions for e-voting are as follows:**

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

**Step 1:** Access to the NSDL e-voting system

**Step 2:** Cast your vote electronically on NSDL e-voting system.

**Step 1: Access to the NSDL e-voting system**

**(A) Login method for e-voting and voting for individual shareholders holding securities in demat mode**





In terms of the SEBI circular dated December 9, 2022 on the e-voting facility provided by listed companies and as part of increasing the efficiency of the voting process, the e-voting



process has been enabled to all individual shareholders holding securities in demat mode to vote through their demat account maintained with depositories and depository participants. Shareholders are advised to update their mobile number and e-mail ID in their demat accounts to access e-voting facility.

Login method for individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> <li>1. Existing <b>IDeAS</b> user can visit the e-Services website of NSDL Viz. <a href="https://eservices.nsd.com">https://eservices.nsd.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the “<b>Beneficial Owner</b>” icon under “<b>Login</b>” which is available under ‘<b>IDeAS</b>’ section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “<b>Access to e-Voting</b>” under e-Voting services and you will be able to see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>2. If you are not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsd.com">https://eservices.nsd.com</a>. Select “<b>Register Online for IDeAS Portal</b>” or click at <a href="https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsd.com/">https://www.evoting.nsd.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>4. Shareholders/Members can also download NSDL Mobile App “<b>NSDL Speede</b>” facility by scanning the QR code mentioned below for seamless voting experience.</li> </ol>

	<p style="text-align: center;"><b>NSDL Mobile App is available on</b></p> <div style="display: flex; justify-content: space-around; align-items: center;">   </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">   </div>
<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<ol style="list-style-type: none"> <li>1) Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on New System Myeasi.</li> <li>2) After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of <b>e-Voting service provider i.e. NSDL</b>. Click on <b>NSDL</b> to cast your vote.</li> <li>3) If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/EasiRegistration</a></li> <li>4) Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. <b>NSDL</b> where the e-Voting is in progress.</li> </ol>
<p>Individual Shareholders (holding securities in demat mode) login through their depository participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>

**Important note:** Members who are unable to retrieve User ID / Password are advised to use “Forgot User ID” and “Forgot Password” options available on the above-mentioned website.

Helpdesk for individual shareholders holding securities in demat mode for any technical issues related to login through depository i.e. NSDL and CDSL

Login Type	Helpdesk Details
Individual shareholders holding securities in demat mode with NSDL	Member facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call the number: 022 – 4886 7000 and 022 – 2499 7000
Individual shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free number: 1800 22 55 33

**(B) Login method of e-voting other than individual shareholders holding securities in demat mode and shareholders holding securities in physical mode**

1. Visit the e-voting website of NSDL. Open the web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a personal computer or on a mobile phone.
2. Once the homepage of the e-voting system is launched, click on the icon “Login”, available under “Shareholder / Member”.
3. A new screen will open. You will have to enter your User ID, Password / OTP and a verification code as shown on the screen.
4. Alternatively, if you are registered for NSDL e-services i.e. IDeAS, you can log in at <https://eservices.nsdl.com/> with your existing IDeAS login. Once you log in to NSDL e-services using your login credentials, click on e-voting and you can proceed to Step 2 i.e., Cast your vote electronically on NSDL e-voting system.
5. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

**6. Password details for shareholders other than individual shareholders are given below:**

- a) If you are already registered for e-voting, then you can use your existing password to log in and cast your vote.
- b) If you are using NSDL e-voting system for the first time, you will need to retrieve the “initial password” which was communicated to you. Once you retrieve your “initial password”, you need to enter the “initial password” for the system to prompt you to change your password.
- c) How to retrieve your “initial password”?

If your email ID is registered in your demat account or with the Company, your ‘Initial Password’ is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e., a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8-digit Client ID for your NSDL account or the last 8 digits of your Client ID for CDSL account. Or Folio Number for shares held in physical form. The .pdf file contains your “User ID” and your “initial password”.

**7. If you are unable to retrieve or have not received the “Initial Password” or have forgotten your password:**

- a. Click on “Forgot User Details / Password?” (If you hold shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b. Physical User Reset Password? (If you hold shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com)
  - c. If you are still unable to get the password by the above two options, you can send a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) mentioning your demat account number / Folio number, your PAN, your name and your registered address.
  - d. Members can also use the OTP (One Time Password)-based login for casting their vote on the e-voting system of NSDL.
8. After entering your password, tick on “Agree with Terms and Conditions” by selecting on the check box.
9. Now, you will have to click on the “Login” button.
10. After you click on the “Login” button, the homepage of e-voting will open.

**Step 2: Cast your vote electronically on NSDL e-voting system**

1. After successfully logging in following Step 1, you will be able to see the EVEN of all companies in which you hold shares and whose voting cycle is in active status.
2. Select the EVEN of Aashka Hospitals Limited
3. Now you are ready for e-voting as the voting page opens.
4. Cast your vote by selecting the appropriate options i.e., assent or dissent, verify / modify the number of shares for which you wish to cast your vote and click on the “Submit” and “Confirm” buttons when prompted.
5. Upon confirmation, the message, “Vote cast successfully”, will be displayed.
6. You can also take a printout of the votes cast by you by clicking on the “Print” option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

Process for procuring your User ID and Password for e-voting for those shareholders whose email Id are not registered with the depositories / Company

1. Shareholders may sent a request to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) for procuring User ID and Password for e-voting.
2. If shares are held in physical mode, please provide Folio number, name of Member, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN), Aadhar (self-attested scanned copy of Aadhar Card)
3. In case shares are held in demat mode, please provide DP ID and Client ID (16-digit DP ID + Client ID or 16-digit beneficiary ID), name of Member, client master or copy of consolidated account statement, PAN (self-attested scanned copy of PAN card), Aadhar (Self attested scanned copy of Aadhar Card).
4. If you are in individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at Step 1 (A) i.e., Login method for e-voting for individual shareholders holding securities in demat mode.

#### **General guidelines for e-voting**

- 1) Institutional Shareholders (i.e., other than individuals, HUF, NRI, etc.) are required to send a scanned copy (PDF / JPG format) of the relevant Board Resolution / authorization letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to [authar-surti.cs@outlook.com](mailto:authar-surti.cs@outlook.com) with a copy marked to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in). Institutional shareholders can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on “Upload Board Resolution / Authority Letter” displayed under “e-Voting” tab in their login.
- 2) It is strongly recommended that you do not share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details / Password?” or “Physical User Reset Password?” option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset password.
- 3) In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for shareholders under the e-voting user manual for shareholders available in the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call the number: 022 – 4886 7000 and 022 – 2499 7000, or send a request to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in), or contact Amit Vishal, Assistant Vice President, or Pallavi Mhatre, Senior Manager, National Securities Depository Limited, at the designated email ID: [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) to get your grievances on e-voting addressed.

## EXPLANATORY STATEMENT

(Pursuant to Section 102 of the Companies Act, 2013)

### **Item No. 3: To Appoint Mr. Umang Ashwinbhai Shah (DIN: 09735002) as an Independent Director of the Company**

Mr. Umang Ashwinbhai Shah (DIN: 09735002) was appointed as an Additional Independent Director of the Company by the Board of Directors vide Board Resolution dated October 7, 2022. Pursuant to the provisions of Section 161(1) and Section 149 of the Companies Act, 2013 and the Articles of Association of the company, he is eligible for appointment. The Company has received a notice in writing under Section 160 of the Companies Act, 2013 (“the Act”) from a member of the Company proposing Mr. Umang Ashwinbhai Shah, as a candidate for the office of a Director.

As per the provisions of Section 149 of the Act, an Independent Director shall hold office for a term up to 5 (five) consecutive years on the Board of a Company and is not liable to retire by rotation. Mr. Umang Ashwinbhai Shah has given a declaration to the Board that he meets the criteria of independence as provided under Section 149(6) of the Act.

The matter regarding appointment of Mr. Umang Ashwinbhai Shah as Independent Director was placed before the Nomination and Remuneration Committee, which recommended his appointment as an Independent Director up to October 6, 2027.

In the opinion of the Board, Mr. Umang Ashwinbhai Shah fulfils the conditions specified in the Act and the Rules made there under for appointment as Independent Director and he is independent of management. The Board has formed an opinion that Mr. Umang Ashwinbhai Shah possesses requisite skills and knowledge and it would be in the interests of the Company to appoint him as an Independent Director of the Company.

In compliance with the provisions of Section 149 read with Schedule IV of the Act, appointment of Mr. Umang Ashwinbhai Shah as an Independent Director is now being placed before the members in this General Meeting for their approval.

The terms and conditions of appointment of Independent Director shall be open for inspection by the members of the Registered Office during normal business hours on any working day of the Company.

Mr. Umang Ashwinbhai Shah is interested and concerned in the Resolution mentioned at Item No 3 of the Notice. Other than Mr. Umang Ashwinbhai Shah, no other Directors, Key Managerial Personnel or their respective relatives are concerned or interested in the Resolutions mentioned at Item No. 3 of the Notice.

The Directors recommend the resolutions for approval by the members as Ordinary Resolution.

**Item No. 4: To re-appoint Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108) as Chairman and Managing Director**

The Board of Directors on the recommendation of Nomination and Remuneration Committee, at their meeting held on March 31, 2023, approved re-appointment of Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108) for the tenure of 3 (Three) years w.e.f. September 20, 2023.

The said appointment is subject to the approval of the shareholders by way of a special resolution. Accordingly, it is now proposed to obtain approval of the shareholders by way of special resolution for appointment of Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108) as the Chairman and Managing Director of the Company w.e.f. September 20, 2023 for a term of 3 (three) years, i.e. up to 19<sup>th</sup> September, 2026.

The following additional information as required under Part II Section II of Schedule V of the Companies Act, 2013 is being furnished hereunder:

**1. General Information:**

- a. **Nature of Industry** – Aashka Hospitals Limited was incorporated on November 9, 2012 with the object to pursue as Medical treatment, Healthcare and Hospital Services.
- b. **Date or expected date of commencement of commercial production** – The Company was incorporated on November 9, 2012 and has been in operations since 2012.
- c. **In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus** – Not applicable
- d. **Financial performance based on given indicators** – The following are the results of the Company for the last 3 (three) years, at glance:

(₹ in Lakhs)

Particulars	2021 – 22	2020 – 21	2019 – 20
Total Income	3,986.14	4,069.23	2,725.14
Net Profit / (Loss) (as per Statement of P & L)	236.52	411.39	134.84
Amount of Equity Dividend	Nil	Nil	Nil
Rate of Equity Dividend	N. A.	N. A.	N. A.

- e. **Foreign investments or collaborations, if any** – There are no foreign investments or collaborations.

**2. Information about the appointee:**

- a. **Background details, recognition and awards** – Mr. Bipinchandra Dineshbhai Shah is the Promoter and Chairman & Managing Director of Aashka Hospitals Limited. He is a Gold Medallist in Civil Engineering and is a Technocrat Entrepreneur with dynamic approach. He has executed an IT SEZ Project in Ahmedabad with a Capex of around ₹ 300 Crores and two leading real estate projects in Gandhinagar. He is also Director of Calica Construction & Impex Private Limited, a leading realty developer Company of Gujarat, which had developed number of Residential and Commercial Projects in the

periphery of Ahmedabad and Gandhinagar. He has rich experience of nearly 30 years in the Real Estate and Construction field.

- b. Past Remuneration** – He has been paid a basic pay of ₹ 10,00,000/- per month along with the perquisites and allowances as per the current remuneration structure
- c. Job Profile and Suitability** – Mr. Bipinchandra Dineshbhai Shah is working as Chairman and Managing Director of the Company. He has carried out the duties as may be entrusted to him by the Directors but subject to supervision and control by Board of Directors, from time to time. Taking into consideration of his qualifications and expertise in the relevant fields, he is suited for the responsibilities assigned to him by the Board of Directors.
- d. Remuneration proposed** – The details of remuneration proposed to be paid to Mr. Bipinchandra Dineshbhai Shah have been provided in the resolution.
- e. Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person** – Taking into account the contribution being made by Mr. Bipinchandra Dineshbhai Shah in the affairs of the Company, his academic background, rich experience, the increasing key role he is playing and considering efforts taken by him in improving the financial position of the Company, the proposed remuneration is reasonable and in lines with the remuneration levels in the industry across the Country.
- f. Pecuniary relationship, directly or indirectly, with the Company or relationship with the managerial personnel, if any** – Mr. Bipinchandra Dineshbhai Shah is a Chairman and Managing Director of the Company and holds 1,28,46,000 Equity Shares of the Company. Mrs. Shreyartha Shah, Director of the Company is spouse of Mr. Bipinchandra Dineshbhai Shah.

### 3. Other Information:

- a. Reasons for Loss / inadequate profits, if any** – The Company has Net Profit of ₹ 236.52 Crores for the FY 2021 – 22 as compared to ₹ 411.39 Crores in FY 2020 – 21. With the rising growth, there has been reduction in profit margins. The profits are in line with the current industrial scenario and are reasonable. There has been significant improvement in the healthcare business services of the Company by providing Category – A services to the satisfaction of patients in the surrounding area of Gandhinagar and also net profits of the Company in last few years. However, the profits are inadequate in terms of payment of remuneration to the Chairman & Managing Director of the Company.
- b. Steps taken / proposed to be taken for improvement** – To increase the turnover of the business, the Company is going to introduce latest technologies and innovations in the medical profession by using state of the art technologies for the better treatment facilities for the patients which will increase the quality of treatment. Further, Company is also looking for tier – III cities for prospective association with the local clinics and doctors for the better treatment services to the small towns and cities.
- c. Expected increase in productivity and profits in measurable terms** – With the increasing health issues in India and growing awareness for pre-emptive treatment for the medical issues, it is expected that the businesses of the Company could improve.



The Board of Directors recommend appointment of Mr. Bipinchandra Dineshbhai Shah as the Chairman and Managing Director of the Company. In light of above, you are requested to accord your approval to the Special Resolution as set out at Agenda Item No. 4 of the accompanying AGM Notice.

Mr. Bipinchandra D. Shah himself and Mrs. Shreyarathi B. Shah, Director of the Company and their relatives may be deemed to be concerned or interested in the said resolution. Except the above, none of the Directors or Key Managerial Personnel of the Company or their relatives has any concern or interest, financial or otherwise, in the proposed resolution.

Registered Office  
Between Sargasan & Reliace Cross Road,  
Sargasan – Gandhinagar, Gandhinagar

By Order of the Board  
For, Aashka Hospitals Limited

Date: 31/03/2023  
Place: Gandhinagar

Bipinchandra Dineshbhai Shah  
Chairman & Managing Director  
DIN: 00934108

**Details of Director seeking appointment / re-appointment at the forthcoming Annual General Meeting**

<b>Particulars</b>	<b>Bipinchandra Shah</b>	<b>Umang Shah</b>
Director Identification Number (DIN)	00934108	09735002
Date of Birth	April 24, 1968	March 14, 1989
Qualification	Bachelor of Engineering (Civil)	B. Pharm.
Experience	He as vast experience in the field of Science and Real Estate. He has been running the Company since Incorporation i.e. Novebmer 9, 2012.	He is in the Business for providing services and advisory into the Finance and Taxations from the last 10 Years
Nature of expertise in specific functional areas	He as vast experience in business management, Science and Real Estate	He has expertise in the field of Finance and Taxations
Terms & Conditions of Appointment / Re – appointment	Shall continue to as Chairman and Managing Director	Shall continue to act as Independent Director w.e.f October 7, 2022 for the tenure of 5 (five) years
Details of Remuneration Sought to be paid	NIL	NIL
Remuneration last Drawn	NIL	NIL
Date of First Appointment on the Board	November 9, 2012	October 7, 2022
Shareholding	1,16,14,400 Equity Shares	NIL
Relationship with Other Directors, Manager or Key Managerial Personnel	Mrs. Shreyarathi Shah, Director is wife	None
No. of Meeting of the Board attended during the year	17	NIL
List of Directorship held in other Companies	1) Calica Construction and Impex Private Limited 2) Aashka Hospitality Private Limited	Nil
Memberships / Chairmanships of Committees of the Board of Other Companies including listed Companies	Nil	Nil
Directorship held in other listed companies	Nil	Nil

Listed entities from which the Director resigned in the past 3 years	Nil	Nil
Skills and capabilities required for the role and the manner in which the proposed person meets such requirements by Independent Director	Not Applicable	He has expertise in the field of Finance and Taxations for more than 10 years. Hence, he possess the necessary skills and capabilities for the role

## BOARD'S REPORT

Dear Shareholders,

Your directors have pleasure in submitting herewith their Annual Report together with the Audited Statement of Accounts for the financial year ended on 31<sup>st</sup> March, 2022.

## FINANCIAL RESULTS

(in ₹ Lakhs)

Particulars	March 31, 2022	March 31, 2021
Revenue from Operations	3,973.36	4,068.88
Other Income	12.78	0.35
<b>Total Income</b>	<b>3,986.14</b>	<b>4,069.23</b>
Total Expenses	3,702.23	3,657.84
<b>Profit / (Loss) before exceptional item and tax</b>	<b>283.91</b>	<b>411.39</b>
Exceptional items	-	-
<b>Profit / (Loss) before tax</b>	<b>283.91</b>	<b>411.39</b>
Less: Tax Expenses	47.39	-
<b>Profit / (Loss) for the year</b>	<b>236.52</b>	<b>411.39</b>

## STATE OF COMPANY'S AFFAIR, OPERATING RESULTS AND PROFITS

Aashka Hospitals is a Multi - Speciality hospital founded in the year 2012, located in the Capital of Gujarat i.e. Gandhinagar. Aashka is an advanced tertiary care medical center, consisting of 150 beds including 65 ICU beds, class 100 modular two cardiac OTs & four dedicated OTs for each super – speciality. Two procedure rooms are available for endoscopy and other minor procedures. All OTs with laminar airflow, HEPA filters & next generation Anesthesia Trolley. Hospital has state of the art flat panel Cath Lab, CT scan, pneumatic transfer system & ultra-modern software driven administration.

Intensive Care Unit (ICU) is a specialized facility dedicated to patients who require intensive monitoring, nursing care and complex respiratory support. The ICU is staffed 24 hours a day by certified specialists and experienced nurses in intensive clinical care. Ultra-modern 65 beaded ICU are equipped with intelligent ventilators, by-phasic AED & pacing defibrillators, modular touch screen multipara monitoring system and centralized Gas supply system.

### • Operation

During the year under review, total earnings has been ₹ 3,986.14 Lakhs as compared to ₹ 4,069.23 Lakhs in the previous year. Profit of the Company after tax stood at ₹ 236.52 Lakhs as compared to ₹ 411.39 Lakhs in the previous year.

The financial year under review continued to pose a challenge due to Covid. The COVID – 19 pandemics played a role in reducing footfalls, and occupancy remained low in the initial part of the financial.

## **STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY**

The Company has adopted a Risk Management Policy for a systematic approach to control risks. The Risk Management Policy of the Company lays down procedures for risk identification, evaluation, monitoring, review and reporting. The Risk Management Policy has been developed and approved by the Senior Management in accordance with the business strategy.

- **Internal control system and their adequacy**

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operation. The scope of Internal Audit is well defined in the organization. The Internal Audit Report regularly placed before the Audit Committee of the Board. The Management monitors and evaluates the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies. Based on the report of Internal Auditor, process owners undertake corrective action in their respective areas and thereby strengthening the controls continuously. The current status of the Company is unlisted due to transfer of the Company to the dissemination Board, and hence the requirement for appointment of Internal Audit for the Financial Year 2020-21 is not applicable now onwards.

### **TRANSFER TO RESERVES**

The Company proposes to retain the profits to profit and loss account and hence, there is no transfer of funds.

### **DIVIDEND**

In order to conserve the profit for future contingencies and due to previous accumulated losses, your directors do not propose for the dividend.

### **TRANSFER TO THE INVESTOR EDUCATION AND PROTECTION FUND**

In accordance with the provisions of sections 124 and 125 of the Act and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules"), dividends of the Company which remained unpaid or unclaimed for a period consecutive seven years from the date of transfer to the unpaid dividend account shall be transferred by the Company to the Investor Education and Protection Fund ("IEPF").

In terms of the foregoing provisions of the Act, the company is not required to transfer any funds or shares to IEPF.

### **DEPOSITS**

The Company has neither accepted nor invited any Deposit falling within the purview of Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 as amended from time to time, during the year under review and therefore details mentioned in Rule 8 (5) (v) & (vi) of Companies (Accounts) Rules, 2014 relating to deposits, covered under Chapter V of the Act is not required to be given.

Further, loans provided by the Directors are being provided by their owned funds and for the same declaration has been provided by the directors.

## **SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES**

The company has no subsidiaries, associates or joint ventures during the period under review.

Further, there has been no subsidiaries, associates or joint venture companies which have ceased during the year.

## **SHARE CAPITAL**

The beginning of the Financial Year Company has Authorised Share Capital of ₹ 18,00,00,000/- (Rupees Eighteen Crores Only) divided into 1,80,00,000 Equity Shares of ₹ 10/- (Rupees Ten Only) each and Issued, Subscribed & Paid-up share Capital is ₹ 18,00,00,000/- (Rupees Eighteen Crores Only) divided into 1,80,00,000 Equity Shares of ₹ 10/- (Rupees Ten Only) each.

Pursuant to the Initial Public Offering on the BSE SME Platform, the Company has made fresh issue of 54,00,000 Equity Shares at a face value of ₹ 10/- each and a premium of ₹ 111/- per share, aggregating to ₹ 6,534 Lakhs

The Revised Share Capital of the Company as on March 31, 2022 is as tabled below:

<b>Particulars</b>	<b>Amount</b>
<b>Authorized Share Capital:</b>	
2,50,00,000 Equity Shares of ₹10/- each	25,00,00,000
<b>Total Authorized Capital</b>	<b>25,00,00,000</b>
<b>Issued Capital</b>	
2,34,00,000 Equity Shares of ₹10/- each	23,40,00,000
<b>Subscribed &amp; Paid – up Capital</b>	
2,34,00,000 Equity Shares of ₹ 10/- each	23,40,00,000
Less: 32,000 Equity Shares of ₹ 10/- each forfeited*	(3,20,000)
<b>Total Paid – up Capital</b>	<b>23,36,80,000</b>

\*The Company has made the allotment for the Initial Public Offering to the eligible applicants as per the Basis of Allotment. However, there were 31 applicants to whom shares were credit to their demat accounts but no application money has been received. Hence, those shares are marked for forfeiture.

## **CHANGE IN THE NATURE OF BUSINESS:**

There has been no considerable change in the business of the Company, during the period under review.

## **MATERIAL CHANGES AND COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE COMPANY**

There has been cessation of Mr. Bhavesh N. Sonesara (Mem. No. 66532) from the post of Compliance Officer and Company Secretary in Whole Time Employment w.e.f. May 16, 2022. Further, the Board has appointed Mr. Umang Ashwinbhai Shah (DIN: 09735002) as Additional

Independent Director, Mr. Lokesh Khandelwal as Chief Financial Officer and Mr. Mayank Agarwal (Mem. No. 55107) as Compliance Officer and Company Secretary in Whole Time Employment w.e.f. October 7, 2022.

In the opinion of the Board of Directors, there are no further material changes and commitments made by the Company occurring between the ends of the financial, which is influential or affecting the financial position of the Company.

## **DIRECTORS AND KEY MANAGERIAL PERSONNEL**

In accordance with the provisions of Section 152 of the Companies Act, 2013 and rules made thereunder, Mr. Bipinchandra Dineshbhai Shah, Chairman & Managing Director of the Company, shall retire by rotation at the ensuing Annual General Meeting and being eligible, had offered himself for re-appointment. The Board recommends his appointment for the consideration of the members of the Company at the ensuing Annual General Meeting.

During the period under review, designation of Mr. Parag Thaker has been changed to Non – Executive Director w.e.f. May 27, 2021. The Company has appointed Mr. Hetang Arunkumar Shah as Independent Director w.e.f. June 24, 2021 who has tendered his resignation w.e.f. March 25, 2022.

Further, Ms. Vidhi Jainik Shah has tendered her resignation as Chief Financial Officer and Mr. Kamlesh Punamchand Patel as Company Secretary w.e.f. October 04, 2021. Accordingly, the Company has appointed Mr. Bhavesh N. Sonasara as Chief Financial Officer and Company Secretary w.e.f. October 4, 2021 who had tendered his resignation as Chief Financial Officer w.e.f. March 28, 2022.

Furthermore, Mr. Kalpeshkumar Parshottamdas Patel has tendered his resignation as Independent Director w.e.f. October 26, 2021.

## **NUMBER OF MEETINGS OF THE BOARD**

The Board meets at regular interval with gap between two meetings not exceeding 120 days. Seventeen (17) Board Meetings were held on April 1, 2021, May 18, 2021, May 27, 2021, June 17, 2021, June 24, 2021, June 26, 2021, July 26, 2021, August 13, 2021, August 18, 2021, August 24, 2021, August 27, 2021, August 30, 2021, October 4, 2021, October 26, 2021, December 10, 2021, January 27, 2022 and March 4, 2022 during the financial year 2021-22.

## **DECLARATION OF INDEPENDENT DIRECTORS**

All the Independent Director of the Company have given their declaration that they meet the criteria of independence as laid down under Section 149 (6) of the Act. In the opinion of the Board, they fulfill the conditions of independence, integrity, expertise and experience (including the proficiency) as specified in the Act and the Rules made there under and are independent of the management.

## FORMAL EVALUATION OF BOARD, COMMITTEE & INDIVIDUAL DIRECTORS

Pursuant to the provisions of the Companies Act, 2013, the Board and its respective members are required to carry out performance evaluation of the board as a body, the Directors individually, Chairman as well as that of its committees.

The Board of Directors of your Company, in order to give objectivity to the evaluation process identified an independent process for conducting board evaluation exercise for its this financial year.

### DISCLOSURE OF VARIOUS COMMITTEE OF BOARD

#### A) AUDIT COMMITTEE

The Audit Committee and the Policy are in compliance with Section 177 of the Companies Act, 2013, read along with the applicable rules thereto.

##### Composition

Sr. No.	Name of the Member	Designation
1.	Hetang Shah <sup>1</sup>	Chairperson
2.	Kalpesh Patel <sup>2</sup>	Member
3.	Shreyarathi B. Shah	Member
4.	Hiteshkumar Ramanlal Shah <sup>3</sup>	Member
5	Umang Ashwinbhai Shah <sup>4</sup>	Member / Chairperson

<sup>1</sup> Ceased w.e.f. March 25, 2022

<sup>2</sup> Ceased w.e.f. October 26, 2021

<sup>3</sup> Appointed w.e.f. October 26, 2021

<sup>4</sup> Appointed w.e.f. October 7, 2022

#### B) NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee and the Policy are in compliance with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto.

##### Composition

Sr. No.	Name of the Member	Designation
1.	Hetang Shah <sup>1</sup>	Chairperson
2.	Kalpesh Patel <sup>2</sup>	Member
3.	Shreyarathi B. Shah	Member
4.	Hiteshkumar Ramanlal Shah <sup>3</sup>	Member
5	Umang Ashwinbhai Shah <sup>4</sup>	Member / Chairperson

<sup>1</sup> Ceased w.e.f. March 25, 2022

<sup>2</sup> Ceased w.e.f. October 26, 2021

<sup>3</sup> Appointed w.e.f. October 26, 2021



<sup>4</sup> Appointed w.e.f. October 7, 2022

### C) STAKEHOLDERS RELATIONSHIP COMMITTEE

Our company has stakeholders' relationship committee as per the provisions of Section 178(5) of the Companies Act, 2013. The constitution of the Stakeholders Relationship Committee is as follows:

Sr. No.	Name of the Member	Designation
1.	Hetang Shah <sup>1</sup>	Chairperson
2.	Bipinchandra Dineshbhai Shah	Member
3.	Shreyarathi B. Shah	Member
4.	Umang Ashwinbhai Shah <sup>2</sup>	Member / Chairperson

<sup>1</sup> Ceased w.e.f. March 25, 2022

<sup>2</sup> Appointed w.e.f. October 7, 2022

### AUDITORS

Pursuant to the provisions of Section 139 of the Act and rules framed thereunder M/s. Singhi & Co., Chartered Accountants, (Firm Registration No. 302049F) were appointed as Statutory Auditors of the Company for a consecutive term of five years to hold office from the conclusion of Annual General Meeting held on September 29, 2018.

### EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE STATUTORY AUDITORS IN THEIR REPORTS

The explanation to the qualifications, reservations or adverse remarks or disclaimers made by the Statutory Auditors in their report are as under:

Sr. No.	Qualifications / Reservations / Adverse Remarks / Disclaimers	Managements' Reply
1.	<i>The company advanced Rs. 2870.42 Lakh to the managing director of the company for the purchase of ready built / plot of land. It has been informed that the said advance is given for the setup of a wellness center of the hospital. The agreements executed between the company and the directors are not provided for verification however Company has deducted and deposited TDS on the transaction</i>	As explained the said amount has been paid by the Company to the Managing Director for the payment towards purchase of Land for the development of Wellness Centre and the Company has deducted TDS for the same.
2.	<i>The company has advanced Rs.2861.50 Lac to three parties with whom it has entered into agreement for acquisition/Tie up with new Hospital. The amounts are classified under the head "Advances given for inorganic growth". As per the agreement provided</i>	As mentioned, the said amount has been paid towards advanced for acquisition / Tie up with new Hospitals or Clinics. The company is in discussion with the parties to recover the interest amount as per Agreement

	<i>to us, the said amounts are given for a period of 12-18 months with interest free period of 180 days. The company has not charged interest there on after that period. We have not been provided with information as tie up /acquisition of any new hospital and clinic.</i>	
3.	<i>The company has advanced Rs.817.12 Lac to 14 parties, for which no documents have been provided to us. The amounts are classified under the head “Advances given to other”. No interest is charged on the said amounts &amp; Confirmation has not been provided</i>	The Company has paid the said amount to various vendors as advances for the development of Wellness Centre. The company is in discussion with the parties to recover the interest amount as per Agreement

### SECRETARIAL AUDITOR

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s. Suthar & Surti, Company Secretaries to undertake the Secretarial Audit of the Company. It is hereby confirmed that the Company has complied with the provisions of SS – 1 i.e. Secretarial Standard on meetings of Board of Directors and SS – 2 i.e. Secretarial Standards on General Meetings. The Report of the Secretarial Auditor for the FY 2021 – 22 is annexed herewith as “**Annexure – A**”.

The details of qualification, reservation or adverse remark on the Secretarial Auditor report is as table below:

<b>Sr. No.</b>	<b>Qualifications / Reservations / Adverse Remarks / Disclaimers</b>	<b>Managements’ Reply</b>
1.	<i>The company has delayed in filing of Half Yearly results for the period ended on September 30, 2021</i>	The Company had originally scheduled the meeting of Board of Directors on November 13, 2021 for consideration of Unaudited Financial for the Half Year ended on September 30, 2021. However, due to hospitalization of Mr. Bhavesh Sonesara, Company Secretary and Chief Financial Officer, the audit process got hampered and was required to reschedule the meeting for the approval to future date. Hence, there was delay in results.
2.	<i>The Company has deviation in utilization of the IPO proceeds</i>	The proceeds of IPO funds have been utilized for the given object. However, the proportion for allocation of funds has been changed. The managements is in process of seeking members approval for the change in utilisation.

## **INTERNAL AUDITOR**

Upon the recommendation of the Audit Committee, the Board of Directors had appointed M/s. Parimal S. Shah & Co., Chartered Accountants as the Internal Auditor for FY 2021 – 22.

## **DETAILS OF FRAUDS REPORT BY THE AUDITOR**

There are no frauds reported by the auditor in its audit report in pursuance to section 143(12) of the Companies Act, 2013, during the period under review.

## **COST AUDITOR**

In terms of Section 148(1) of the Companies Act, 2013, the Cost Audit is not applicable to the Company.

## **DIRECTORS' RESPONSIBILITY STATEMENT**

In terms of Section 134 (3) (c) of the Companies Act, 2013 in relation to the financial statements for the year 2021- 22, the Board of Directors state that:

- a) In preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company for the financial year ended on March 31, 2022 and of the profit and loss of the company for that period;
- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis; and
- e) The directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## **PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE COMPANIES ACT, 2013**

Details of investments, loans and guarantee under the provisions of Section 186 of the Companies Act, 2013 read with the Companies (Meeting of Board and its Powers) Rules, 2014, as on 31<sup>st</sup> March, 2022, are set out in Notes to Financial Statements forming part of this report.

## **CORPORATE SOCIAL RESPONSIBILITY INITIATIVES AND POLICY**

The provisions of Section 135(1) of the Companies Act, 2013, for the Corporate Social Responsibility are not applicable to the company.

## RELATED PARTY TRANSACTIONS:

All the contracts or arrangements entered by the Company during the financial year with related parties were in the ordinary course of business and on arm's length basis. During the year under review, the Company has entered into contracts or arrangements with related parties, which are material contracts or transaction on arms' length basis, which has been provided in Form AOC – 2 and appended as “Annexure – B”.

All related party transactions are presented to the Audit Committee and Board for approval. The Policy on Related Party Transactions as approved by the Board is available on Company's website.

## BUSINESS RISK MANAGEMENT

The Company has formulated Risk Management Policy in order to monitor the risks and to address/ mitigate those risks associated with the Company. The Board of Directors do not foresee any elements of risk, which in its opinion may threaten the existence of the Company.

## COMPANY'S POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION INCLUDING CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES, INDEPENDENCE OF A DIRECTOR AND OTHER MATTER

The Board has, on the recommendation of the Nomination & Remuneration Committee framed a remuneration policy for selection and appointment of Directors, Senior Management and their remuneration including criteria for determining qualifications, positive attributes, independence of a Director etc. and the same is also available on the website of the Company at the link <https://aashkahospitals.in/wp-content/uploads/2021/08/G-Nomination-and-Remuneration-Policy.pdf>

## MANAGERIAL REMUNERATION

Disclosure pursuant to Rule 5 of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with Schedule V of the Companies Act, 2013 are as under:

- 1) **The ratio of the remuneration of each director to the median remuneration of the employees of the Company for the Financial Year**

Sr. No.	Name of the Director	Designation	Remuneration Paid	Medium Remuneration	Ratio to Median Remuneration
1.	Bipinchandra Dineshbhai Shah	Chairman & Managing Director	₹ 1,20,00,000	₹ 1,05,483	113.76:1

- 2) The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, during the financial year under review

Sr. No.	Name of Director / KMP	Designation	% increase in Remuneration
1.	Bipinchandra Dineshbhai Shah	Chairman & Managing Director	42.86%
2.	*Kamlesh Punamchand Patel	Company Secretary & Compliance Officer	0%
3.	#Bhavesh Nareshbhai Sonesara	Chief Financial Officer, Company Secretary & Compliance Officer	0%

\*Ceased w.e.f. October 4, 2021

# Appointed w.e.f. October 4, 2021 and ceased as Chief Financial Officer w.e.f. March 28, 2022.

- 3) The percentage increase in the median remuneration of employees in the Financial Year
- 4) The number of permanent employees on the rolls of the Company – There are 324 employees during the reporting period.
- 5) Average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration – The median percentage increase in salaries of employees other than the managerial personnel is 148.52% as compared to remuneration increase in Managerial Personnel is 433%.
- 6) **Affirmation** – It is hereby affirmed that the remuneration paid to the Managerial Personnel is as per the remuneration policy of the Company.

#### Corporate Governance – Disclosure

- 7) All Elements of Remuneration Package of all the Directors

Sr. No.	Name	Salary	Benefits	Bonuses	Stock Options	Pension
1.	Bipinchandra Dineshbhai Shah	₹1,20,00,000	P.F., Gratuity, Perquisites, etc.	-	-	-

- 8) Details of Fixed component and performance linked incentives along with the performance criteria – Not Applicable

**9) Service contracts, notice period, severance fees – Not Applicable**

**10) Stock Option details, if any, and whether the same has been issued at a discount as well as the period over which accrued and over which exercisable – There are no stock option in the company.**

**PARTICULARS OF EMPLOYEES:**

Pursuant to the Sub – Rule (2) of the Rule 5 of the Companies (Appointment & Remuneration or Managerial Personnel) Rules, 2014, read with Section 197 of the Act, no employees was in receipt of the remuneration in aggregate to ₹ 102 lacs per annum or ₹ 8.5 lacs per month or at a rate in excess of that drawn by the Managing Director / Whole – time director of Manager and holds himself or along with his spouse & dependent children, no less than two percent of the equity shares of the Company. In terms of Section 136 of the Act, the Report and Accounts are being sent to the Members and others entitled thereto, excluding the information on employees’ particulars which is available for inspection by the Members at the Registered Office of the Company during the business hours on working days of the Company up to the date of the ensuing Annual General Meeting.

**WEBLINK OF THE ANNUAL RETURN:**

The copy of Annual Return in Form MGT – 7 for the financial year ending March 31, 2022 has been placed on the web portal of the company at [www.aashkahospitals.in](http://www.aashkahospitals.in) under Investor section.

**SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:**

There are no significant material orders passed by the Regulators or Courts or Tribunals impacting the going concern status of your Company and its operations in future.

**DISCLOSURE AS PER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ATC, 2013:**

The Company has zero tolerance for sexual harassment at workplace and has adopted a policy against sexual harassment in line with the provisions of Sexual Harassment of Women at Work place (Prevention, Prohibition & Redressal) Act, 2013 and the rules framed thereunder. Pursuant to the provisions of “The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013” and rules made thereunder, the Company has formed an Internal Complaint Committee.

During the financial year 2021-22, the Company has not received any complaints on sexual harassment and hence no complaints remain pending as at 31<sup>st</sup> March, 2022.

**CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO:**

**(A) CONSERVATION OF ENERGY -**

**(i) Steps taken or impact on conservation of energy;**

1. Use of high efficiency welding machine against conventional welding machine.

2. Replacement of low efficiency electric motors with high efficiency electric motors.
3. Replacement of conventional tube light by LED at various locations. .

**(ii) Steps taken by the Company for utilising alternate sources of energy;**  
Company has decided to utilize solar power for domestic usage.

**(iii) Capital investment on energy conservation equipment;**

- 1.The Company continuously makes investments in its facility for better maintenance and safety of the operations.
- 2.The Company has undertaken efforts to improve the existing facilities in order to reduce energy consumption.

**(B) TECHNOLOGY ABSORPTION -**

**(i) Efforts made towards technology absorption;**

The Company is planning to utilize waste heat of process to reduce natural gas consumption.

**(ii) Benefits derived as a result of the above efforts:**

Specific consumption of energy is reduced, cost reduction and increase in sales.

**(iii) Information regarding technology imported, during the last 3 years: Nil**

**(iv) Expenditure incurred on Research and Development: Nil**

**(C) Foreign Exchange Earnings and Outgo -**

(a) Foreign Exchange Earnings: Nil

(b) Foreign Exchange Out go: Nil

**MANAGEMENT DISCUSSION AND ANALYSIS REPORT**

In terms of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, details on Management Discussion and Analysis Report are annexed as “Annexure – C”.

**ACKNOWLEDGEMENTS**

The Directors wish to place on record their appreciation, for the contribution made by the employees, at all levels but for whose hard work, and support, the Company’s achievement would not have been possible. The Directors also wish to thank its customers, dealers, agents, suppliers, investors and bankers for their continued support and faith reposed in the Company.

Registered Office  
Between Sargasan & Reliance Cross Road,  
Sargasan, Gandhinagar – 382421

By Order of the Board  
For, Aashka Hospitals Limited

Date: 31/03/2023  
Place: Gandhinagar

Bipinchandra Dineshbhai Shah  
Chairman & Managing Director  
DIN: 00934108

**ANNEXURE -A**

**Form No. MR – 3**

*[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]*

**SECRETARIAL AUDIT REPORT**

For the Financial Year ended March 31, 2022

**To,**  
**The Members**  
**Aashka Hospitals Limited**  
**CIN: L85110GJ2012PLC072647**  
**Between Sargasan & Reliance Cross Road,**  
**Sargasan, Gandhinagar – 382421**

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Aashka Hospitals Limited** (hereinafter called as “**the Company**”). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Based on our verification of the books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on **March 31, 2022** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and Compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on **March 31, 2022** according to the provisions of:

- 1) The Companies Act, 2013 (the Act) and the Rules made thereunder;
- 2) The Securities Contracts (Regulation) Act, 1956 (‘SCRA’) and the Rules made thereunder;
- 3) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- 4) Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder;
- 5) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (‘SEBI Act’): -
  - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; (**not applicable during the period under review**)
  - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;



- c) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; **(not applicable during the period under review)**
- d) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **(not applicable during the period under review)**
- e) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- f) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **(not applicable during the period under review)**
- g) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **(not applicable during the period under review)**
- h) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018;
- i) The following laws are industry specific laws as applicable to the Company:
  - i. Indian Medical Council Act, 1956 and Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002;
  - ii. Indian Medical Degree Act, 1916;
  - iii. The Indian Medical Association;
  - iv. Indian Nursing Council Act, 1947;
  - v. The National Medical Commission Bill, 2019;
  - vi. Gujarat Medical Council Act, 1967;
  - vii. Gujarat Medical Practitioners' Act, 1963;
  - viii. Clinical Establishments (Registration & Regulation) Act, 2010;
  - ix. The Drugs Control Act, 1950;
  - x. Drugs and Cosmetics Act, 1940 and Amendment Act, 1982;
  - xi. Narcotic Drugs and Psychotropic Substances Act, 1985;
  - xii. Pharmacy Act, 1948;
  - xiii. Sale of Goods Act, 1930;
  - xiv. Medical Termination of Pregnancy Act, 1971;
  - xv. Transplantation of Human Organs Act, 1994;
  - xvi. Pre-conception and Pre-natal Diagnostic Techniques Act, 1994;
  - xvii. Registration of Births and Deaths Act, 1969;
  - xviii. Atomic Energy Act, 1962 and Atomic Energy (Radiation Protection) Rules, 2004;
  - xix. Safety Code for Medical Diagnostic X – Ray Equipment and Installations, 2001;
  - xx. Radiation Surveillance Procedures for Medical Application of Radiation; 1989;
  - xxi. Central Government Health Scheme, 1954;
  - xxii. The Gujarat Emergency Medical Services Act, 2007;
  - xxiii. Consumer Protection Act, 1986;
  - xxiv. Ethical Guidelines for Biomedical Research on Human Participants, 2006;
  - xxv. Food Safety and Standards Act, 2006;

- xxvi. Environment (Protection) Act, 1986;
- xxvii. Water (Prevention and Control of Pollution) Act, 1974 and Water (Prevention and Control of Pollution) Cess Act, 1977;
- xxviii. Air (Prevention and Control of Pollution) Act, 1981;
- xxix. Biomedical Waste Management Rules, 2016;
- xxx. Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016;
- xxxi. Public Liability Insurance Act, 1991;
- xxxii. Noise Pollution Control Rule, 2000;
- xxxiii. Public Health Bye Law 1959;

We have also examined compliance with the applicable clauses of the following:

- 1) Secretarial Standards issued by the Institute of Company Secretaries of India.
- 2) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015.

We further report, that compliance by the Company of applicable financial laws, like direct and indirect tax laws, has not been reviewed in this Audit since the same have been subject to review by Tax Auditor / Other designated professionals.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above, except for the followings:

- 1) *The company has delayed in filing of Half Yearly results for the period ended on September 30, 2021*
- 2) *The Company has deviation in utilization of the IPO proceeds*

#### **We further report that**

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and details notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board as the case may be.

**We further report that** there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**We further report that** during the audit period the following specific events / actions took place which have a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.:

- 1) The Company has increased the Authorized Share Capital of the Company from ₹ 18,00,00,000/- to ₹25,00,00,000/-.
- 2) The Company has issued and allotted Equity Shares in accordance with the Initial Public Offering ("IPO") on the SME Platform of BSE Limited.

**For, Suthar & Surti**  
**Company Secretaries**  
**UCN: P2018GJ068000**

**Jay Surti**  
**Partner**  
**Mem. No.: F11534**  
**COP No.: 18712**  
**UDIN: F011534D003346822**

**Date: 30/03/2023**  
**Place: Ahmedabad**

## **Annexure to the Secretarial Audit Report**

**To,  
The Members  
Aashka Hospitals Limited  
CIN: L85110GJ2012PLC072647  
Between Sargasan & Reliance Cross Road,  
Sargasan, Gandhinagar – 382421**

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness of appropriateness of financial records and books of accounts of the Company.
4. Wherever required, we have obtained the Management Representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For, Suthar & Surti  
Company Secretaries  
UCN: P2018GJ068000**

**Jay Surti  
Partner  
Mem. No.: F11534  
COP No.: 18712  
UDIN: F011534D003346822**

**Date: 30/03/2023  
Place: Ahmedabad**

## ANNEXURE – B

### Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

#### 1. Details of contracts or arrangements or transactions not at arm's length basis:

Name(s) of the Related Party & Nature of relationship	Nature of transaction	Duration of Transaction	Salient Terms of transaction including the value, if any	Justification for entering into such transactions	Date(s) of approval by the Board	Amount paid as advances, if any	Date of passing of resolution under first proviso of Sec 188(1)
N. A.	N. A.	N. A.	N. A.	N. A.	N. A.	N. A.	N. A.

#### 2. Details of material contracts or arrangement or transactions at arm's length basis:

Name(s) of the Related Party & Nature of relationship	Nature of transaction	Duration of transaction	Salient Terms of transaction including the value, if any	Date(s) of approval by the Board, if any	Amount paid as advance, if any
Mr. Bipinchandra Dineshbhai Shah (Chairman & Managing Director)	Purchase of Property	N.A.	N.A.	April 1, 2021	N.A.

Registered Office  
Between Sargasan & Reliance Cross Road,  
Sargasan, Gandhinagar – 382421

By Order of the Board  
For, Aashka Hospitals Limited

Date: 31/03/2023  
Place: Gandhinagar

Bipinchandra Dineshbhai Shah  
Chairman & Managing Director  
DIN: 00934108

## **ANNEXURE – C**

### **MANAGEMENT DISCUSSION AND ANALYSIS REPORT**

#### **INDUSTRY STRUCTURE AND DEVELOPMENTS**

The overall economic development and rising population of the country has led the Healthcare sector to become one of the largest sectors of the Indian economy, both in terms of revenue and employment.

Several factors continue to drive the growth of the Indian Healthcare sector including an aging population, a growing middle class and significant level of awareness, the rising proportion of lifestyle diseases, expanding health insurance coverage as well as accelerated adoption of digital technologies.

The Indian Government is further strengthening the healthcare sector by undertaking structural and sustained reforms and has been announcing conducive policies for encouraging FDI. The Aatmanirbhar Bharat Abhiyaan packages include several short – term and longer – term measures for the health system, including Production – Linked Incentive (PLI) schemes for boosting domestic manufacturing of pharmaceuticals and medical devices. Additionally, India is working towards becoming a hub for spiritual and wellness tourism, as the country has much to offer in Ayurveda and Yoga.

India’s healthcare industry largely comprises the key segments of hospitals, pharmaceuticals, diagnostics, medical devices and equipment, health insurance and medical tourism. India has emerged as one of the fastest – growing emerging economies over the last two decades, receiving significant FDI inflows. A slew of investments by global healthcare players have strengthened the perception of India as an attractive healthcare investment destination.

In the hospital segment, the expansion of private players to Tier 2 and Tier 3 locations, beyond metropolitan cities, offers an attractive investment Opportunity. In the medical devices and equipment segment, expansion of diagnostic and pathology centres as well as miniaturized diagnostics have high potential for growth. Medical Value Travel especially wellness tourism, also has bright prospects, given India’s inherent strengths in alternative systems of medicine.

#### **OPPORTUNITIES AND THREATS**

The demand for healthcare services in India is expected to remain strong primarily driven by ageing population, burgeoning lifestyle diseases, rising affordability which in turn drives quality healthcare and improving medical insurance penetration. We believe hospital’s segment being the largest component of the overall healthcare industry will be the biggest beneficiaries of the healthcare market in India as public spend likely to be limited to ~25-30% of annual healthcare spend.

Medical tourism is expected to be one of significant growth drivers for India’s Healthcare Sector. India offers a significant cost advantage globally along with best – in – class clinical

outcomes.

## **OUTLOOK**

The United Nations has raised India's growth forecast to 7.5 per cent for calendar year 2021, marking a 0.2 per cent increase from its projection in January, but said the country's outlook for the year remains highly fragile. The surging Covid-19 infections and inadequate vaccination progress in many countries threaten a broad-based recovery of the world economy, said the World Economic Situation and Prospects report.

A report by OECD says that after recording the strongest GDP rebound in the G20 in 2021, the Indian economy is progressively losing momentum as inflationary expectations remain elevated due to rising global energy and food prices, monetary policy normalises and global conditions deteriorate. Real GDP is projected to grow by 6.9% in fiscal year (FY) 2022 – 23 and 6.2% in FY 2023 – 24, despite a pick – up of corporate investment facilitated by the PLI Scheme.

Private healthcare players will continue to play a critical role in the healthcare industry as they continue to provide healthcare services to more than 70% rural population and 80% urban population in India. In addition, private healthcare players will continue to invest heavily which will entail addition to new bed capacity, bringing in new high end medical infrastructure, uplifting the overall healthcare services in the country by adopting new technologies which should further enhance the overall experience of the patients.

## **RISKS AND CONCERNS**

Risks are an unavoidable and integral part of any enterprise. Efficient management of business risks is a key factor that determines growth, profitability and at times, even survival. In the last few years, the healthcare industry in India has been witnessing increased consolidation even among the larger players. Further, Government intervention, by way of an active regulatory regime, be it in terms of price control or capping of margins on medicines and implants has been stepped up. State and Central Healthcare coverage schemes are also impacting industry margins.

At Aashka Hospitals, we continue to strive for a focused approach on risk identification, management and mitigation. We are documenting operational risks and concerns at the unit level as well as the strategic and financial risks at the enterprise level in the form of a robust risk register. The aim is to improve responsibility accounting and bring the right stakeholders to focus on appropriate risk mitigation and monitoring measures at various levels within an organisation.

## **INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY**

The internal control system has been designed to commensurate with the nature of business and complexity of operations and is monitored by the management to provide reasonable assurance on the achievement of objectives, effectiveness and efficiency of operations, reliability of financial reporting and compliance with applicable laws and regulations. The

Company has institutionalized a robust process and internal control system commensurate with its size and operations.

## **DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATION PERFORMANCE**

During the year under review, total earnings has been ₹ 3,986.14 Lakhs as compared to ₹ 4,069.23 Lakhs in the previous year. Profit of the Company after tax stood at ₹ 236.52 Lakhs as compared to ₹ 411.39 Lakhs in the previous year.

The financial year under review continued to pose a challenge due to Covid. The COVID – 19 pandemics played a role in reducing footfalls, and occupancy remained low in the initial part of the financial.

## **HUMAN RESOURCE**

The primary objective of any human resource management is to ensure the availability of competent and willing workforce to the organisation as well as to meet the needs, aspirations, values and dignity of individuals / employees and having due concern for the socio – economic problems of the community and the country. During the year, your company focused on these objectives keeping mind the disastrous Covid Pandemic that has engulfed the entire world.

During the period under review, the company had 324 employees on roll.

## **DETAILS OF SIGNIFICANT CHANGES (I.E. CHANGE OF 25% OR MORE AS COMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR) IN KEY FINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREFOR**

<b>Sr. No.</b>	<b>Particulars</b>	<b>FY 2021 – 22</b>	<b>FY 2020 – 21</b>	<b>Remarks</b>
1.	Debtors Turnover Ratio	5.25	5.79	-
2.	Inventory Turnover Ratio	73.02	69.07	-
3.	Interest Coverage Ratio	1.85	1.07	There has been increase of 73% in Interest Coverage, as the Interest Cost of the Company has reduced due to repayment of borrowings from the IPO proceeds
4.	Current Ratio	0.82	1.01	-
5.	Debt Equity Ratio	0.34	1.23	There has been reduction of 73% in the Debt Equity ratio due to repayment of Borrowings by the



				company from the IPO proceeds
6.	Operating Profit Margin (%)	13.78	17.96	-
7.	Net Profit Margin (%)	5.93	10.11	There has been reduction of 41% in Net Profit margins, due to higher Operating Cost
8.	Return on Net Worth	2.51	16.37	There has been reduction of 85% on Return on Net Worth due to dilution of Equity through IPO and lower Net Profit Margins

# INDEPENDENT AUDITOR'S REPORT

To  
The Members of  
AASHKA HOSPITALS LIMITED

## Report on the Financial Statements

### Qualified Opinion

We have audited the Financial Statements of **AASHKA HOSPITALS LIMITED** ("the Company"), which comprises the Balance Sheet as at **31<sup>st</sup> March, 2022**, and the Statement of Profit and Loss, Cash Flow Statement and Notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2022 and its Profit and its Cash Flows for the year ended on that date except for the matter stated in Basis of Qualified opinion paragraph below:

### Basis of Qualified opinion

- 1. The company advanced Rs. 2870.42 Lakh to the managing director of the company for the purchase of ready built / plot of land. It has been informed that the said advance is given for the setup of a wellness center of the hospital. The agreements executed between the company and the director are not provided for verification however Company has deducted and deposited TDS on the transaction.***
- 2. The company has advanced Rs.2861.50 Lac to three parties with whom it has entered into agreement for acquisition/Tie up with new Hospital. The amounts are classified under the head "Advances given for inorganic growth". As per the agreement provided to us, the said amounts are given for a period of 12-18 months with interest free period of 180 days. The company has not charged interest there on after that period. We have not been provided with information as tie up /acquisition of any new hospital and clinic.***
- 3. The company has advanced Rs.817.12 Lac to 14 parties, for which no documents have been provided to us. The amounts are classified under the head "Advances given to other". No interest is charged on the said amounts. Confirmation has not been provided.***

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance

with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Information other than the Financial Statements and Auditor's Report Thereon**

The Company's Board of Directors and Management is responsible for the preparation of the other information. The other information comprises the information obtained at the date of this auditor's report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact. We have nothing to report in this regard

### **Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

### **Responsibility of Management for Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered

material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless

law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-Section (11) of Section 143 of the Companies Act, 2013, We give in the "**Annexure A**" statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet and Statement of Profit & Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
  - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f) With respect to the adequacy of the Internal financial control over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "**Annexure B**". Our reports express an unmodified opinion on the adequacy and reporting effectiveness of the Company's internal financial controls over financial reporting.
  - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
    - i. The Company does not have any pending litigations which would impact its Financial Position.
    - ii. The Company did not have any material foreseeable losses on long-term contracts including derivative contracts.
    - iii. The Company is not required to transfer any amounts to the Investors Education and Protection Fund.
    - iv. (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies),

including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(ii) The management has represented, that, to the best of it’s knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(iii) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.

- v. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.
- vi. With respect to the matter to be included in the Auditors’ Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the remuneration paid during the current year by the company to its director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197 of the Act which are required to be commented upon by us.

**For, SINGHI & CO.  
Chartered Accountants  
FRN NO: 302049E**

**SUNIL C BOHARA  
Partner  
Membership No. 103395  
UDIN: 23103395BGXTMN2771**

**Ahmedabad, 18<sup>th</sup> January 2023**

## **ANNEXURE” A” TO THE INDEPENDENT AUDITOR'S REPORT**

Referred to in paragraph 1 under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date to the financial statements of the Company for the year ended March 31<sup>st</sup>, 2022:

1. In respect of the Company's Property Plant & Equipment:
  - (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment
  - (b) The Company has maintained proper records showing full particulars of Intangible Assets.
  - (c) As explained to us, Property Plant & Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
  - (d) The title deeds of immovable properties as disclosed in Note 10 on Fixed Assets to the Financial Statements are held in the name of Company.
  - (e) The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) and/or Intangible Assets during the year. Accordingly, reporting under clause (i)(d) of paragraph 3 of the Order is not applicable.
  - (f) No proceedings have been initiated or are pending against the Company as at March 31, 2022 for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
2. In respect of Company's inventories:
  - (a) The management during the year has conducted physical verification of the inventories & in our opinion the frequency of verification is reasonable.
  - (b) In our opinion and according to the information and explanations given to us, the Company has maintained proper records of inventory. The discrepancies noticed on verification between the physical stocks and the book records were not material and have been properly dealt with in the books of accounts.
  - (c) The Company has been sanctioned working capital limits in excess of five crore rupees during the year, in aggregate from banks and/or financial institutions, on the basis of security of current assets. The quarterly returns/statements filed by the Company with such banks and/or financial institutions are in agreement with the books of account of the Company.
3. During the year, the Company has not made investments in, provided any guarantee or security or granted any loans, secured or unsecured to Companies, Firms, Limited Liability Partnerships or other parties covered in the Register maintained under Section 189 of the Act. Accordingly, the provisions of Clause 3 (iii) (a) to (f) of the Order are not applicable to the Company and hence not commented upon.
4. In our opinion and according to the information and explanations given to us, The Company has complied with the provisions of sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities
5. In our opinion and according to the information and explanations given to us, the Company has not accepted deposits from the public during the year. Therefore, the directives issued by the Reserve

Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions with regards to deposits are not applicable to the Company.

6. As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the Company.
7. **(a) According to the records of the Company, undisputed statutory dues including Goods and Services tax (GST), provident fund, employees' state insurance, income-tax, duty of customs and Cess to the extent applicable and any other statutory dues have not been—regularly deposited with the appropriate authorities.**

(b) According to the information and explanations given to us, no undisputed amounts payable in respect of Goods and Services tax (GST), provident fund, employees' state insurance, income-tax, duty of customs and Cess were in arrears as on 31st of March, 2022 for a period of more than six months from the date they became payable except as follows:

**Statement of Arrears of Statutory Dues Outstanding for More than Six Months**

Name of the statute	Nature of the dues	Amount	Period to which the amount relates	Due Date	Date of Payment	Remarks, if any
Direct Tax -TDS	TDS on sales of Property.	28,42,000/-	March-22	30/04/2022	30/12/2022	Paid

(c) There are no dues referred to in above paragraph which have not been deposited on account of any dispute.

8. As per information & explanation provided by the management there are no transaction(s) which were previously not recorded in the books of account of the Company that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
9. (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of dues to Financial Institutions, Banks and Debentures Holders. Also the Company has not taken any further loan from Financial Institutions or from the government and has not issued any debentures.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution government or any government authority.
- (c) The Company has prima facie utilized the money obtained by way of term loans during the year for the purposes for which they were obtained.
- (d) On an overall examination of the financial statements of the Company, no funds raised on short-term basis have, been used for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures as defined under the Act.
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies, as defined under the Act.



10. **Based upon the audit procedures performed and the information and explanations given by the management, The Company has utilized the money raised by way of initial Public issue offer/further public offer (including debt instruments) during the year for the purpose for which they were raised, except the details given below.**

Description	Amount ( Rs. in Cr)			
Money Raised through IPO	101.64			
Less: - Selling Shareholders	36.30			
Less :- Offer Expenses to the extent applicable to the Fresh Issue	1.80			
Net Proceed received by the Company	63.54			
<b>Amount (Rs. in Cr)</b>				
<b>Purpose Shown in the Prospectus</b>				
Description	Amount to be funded from Net Proceeds	Estimate Utilization of Net Proceeds		
		F Y 2021-22	F Y 2022-23	F Y 2023-24
Repayment of Loan	20.00	20.00	--	--
Funding for Inorganic Growth Initiatives	28.54	4.00	16.00	8.54
General Corporate Purpose	15.00	15.00	--	--
<b>Total....</b>	<b>63.54</b>	<b>39.00</b>	<b>16.00</b>	<b>8.54</b>
<b>Amount Utilized till Balance Sheet Date(31/03/2022)</b>				
Repayment of Loan		8.78	--	--
Advance given for Inorganic Growth Initiatives		28.62	--	--
General Corporate Purpose/Other Use		25.29	--	--
Subscription amount not received		0.39	--	--
Balance in Escrow Account		0.46	--	--
<b>Total....</b>		<b>63.54</b>	<b>--</b>	<b>--</b>
<b>Amount to be utilized for the Specific Purpose mentioned in the Prospectus</b>				
Repayment of Loan		11.22	--	--
Funding for Inorganic Growth Initiatives		--	--	-
General Corporate Purpose		--	--	--
<b>Total....</b>		<b>11.22</b>	<b>--</b>	<b>--</b>

11. Based upon the audit procedures performed and the information and explanations given by the management, The Company has not made preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year and in our opinion, the requirements of section 42 and section 62 of the Act have been complied with and the funds raised have been used for the purpose(s) for which they were raised.
12. (a) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the Company has been noticed or reported during the year.
- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- (c) There are no whistle blower complaints received by the Company during the year and upto the date of this report.
13. The Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.

14. According to information and explanation given to us and based on our examination of the records of the Company, all the transactions with the related parties are in compliance with Section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the financial statements as required by the applicable accounting standards.
15. (a) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the Internal Audit Reports of the Company issued till date, for the period under audit.
16. Based upon the audit procedures performed and the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.
17. The Company is not required to be registered under section 45IA of the Reserve Bank of India Act, 1934 and accordingly, the Provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.
18. The Company has not incurred cash losses in the current and the immediately preceding financial year.
19. There has been no resignation of the statutory auditors during the year and accordingly, reporting under clause (xviii) of paragraph 3 of the Order is not applicable.
20. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, **we are of the view that the company may face difficulty in paying /meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. However if the company is able to bring back the funds advanced then it may be able to meet its liabilities.** We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
21. The provisions of section 135 of the Act are not applicable to the Company. Hence, reporting under clause (xxi) of paragraph 3 of the Order is not applicable.

**For, SINGHI & CO.**  
**Chartered Accountants**  
**FRN NO: 302049E**

**SUNIL C BOHARA**  
**Partner**  
**Membership No. 103395**  
**UDIN: 23103395BGXTMN2771**

**Ahmedabad, 18<sup>th</sup> January 2023**

## **ANNEXURE “B” TO THE INDEPENDENT AUDITOR’S REPORT**

(Referred to in paragraph 2(f) under “Report on Other Legal and regulatory requirements’ of our report of even date)

### **Report on the Internal Financial Controls under Clause (i) of Sub-Section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **AASHKA HOSPITALS LIMITED** (“the Company”) as of 31<sup>st</sup> March 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (‘ICAI’). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls over Financial Reporting**

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31<sup>st</sup> March 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For, SINGHI & CO.  
Chartered Accountants  
FRN NO: 302049E**

**SUNIL C BOHARA  
Partner  
Membership No. 103395  
UDIN: 23103395BGXTMN2771**

**Ahmedabad, 18<sup>th</sup> January 2023**

# AASHKA HOSPITALS LIMITED

BETWEEN SARGASAN & RELIANCE CROSS ROAD, SARGASAN, GANDHINAGAR-382421

CIN :- L85110GJ2012PLC072647

## BALANCE SHEET AS AT 31ST MARCH 2022

(₹ in Lac, except for share data and if otherwise stated)

Particulars	Note No.	As at 31st March 2022	As at 31st March 2021
		₹	₹
<b>I. EQUITY AND LIABILITIES</b>			
<b>(1) Shareholders' Funds</b>			
(a) Share Capital	1	2,336.80	1,800.00
(b) Reserves and Surplus	2	7,319.63	1,124.62
<b>(2) Share Application Money Pending Allotment</b>		-	-
<b>(3) Non-Current Liabilities</b>			
(a) Long-Term Borrowings	3	1,677.37	2,016.12
(b) Other Long Term Liabilities	4	50.40	50.40
(c) Long Term Provisions	5	21.38	13.10
<b>(4) Current Liabilities</b>			
(a) Short Term Borrowing	6	1,143.94	770.66
(b) Trade Payable	7	158.87	429.67
(c) Other Current Liabilities	8	62.67	204.30
(d) Short Term Provisions	9	140.70	99.26
<b>Total</b>		<b>12,911.76</b>	<b>6,508.14</b>
<b>II.Assets</b>			
<b>(1) Non-current assets</b>			
(a) Property, Plant & Equipments & Intangible Asstes			
(i) Property, Plant & Equipments	10	4,846.03	4,949.23
(ii) Intangible Assets		-	-
(iii) Capital Work-in-Progress		-	-
(iv) Intangible Assets under Development		-	-
(b) Non-Current Investments		-	-
(c) Other Non Current Assets	11	6,825.37	191.35
<b>(2) Current assets</b>			
(a) Inventories	12	54.52	54.30
(b) Trade Receivables	13	781.88	731.62
(c) Cash and Cash Equivalents	14	106.90	292.66
(d) Short-Term Loans and Advances	15	6.51	6.88
(e) Other Current Assets	16	290.54	282.10
<b>SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PARTS OF ACCOUNTS</b>			
	26		
<b>Total</b>		<b>12,911.76</b>	<b>6,508.14</b>

For and on behalf of  
SINGHI & CO.  
Chartered Accountants  
FRN : 302049E

SUNIL C BOHARA  
Partner  
M. No.103395  
UDIN:23103395BGXTMN2771

Ahmedabad, 18th January 2023

For and on behalf of the Board of Directors

BIPIN SHAH  
Managing Director  
Din No:- 00934108

LOKESH KHANDELWAL  
CFO

Ahmedabad, 18th January 2023

SHREYARTHI BIPIN SHAH  
Director  
Din No :- 02253942

MAYANK AGARWAL  
Company Seceratry

# AASHKA HOSPITALS LIMITED

BETWEEN SARGASAN & RELIANCE CROSS ROAD, SARGASAN, GANDHINAGAR-382421

CIN :- L85110GJ2012PLC072647

## STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2022

(₹ in Lac, except for share data and if otherwise stated)

	Particulars	Note No.	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
			₹	₹
	<b>Income:</b>			
I	Revenue from Operations	17	3,973.36	4,068.88
II	Other Income	18	12.78	0.35
III	<b>Total Income (I +II)</b>		<b>3,986.14</b>	<b>4,069.23</b>
IV	<b>Expenses:</b>			
	Purchase	19	573.75	642.44
	Changes in Inventories of Finished Goods and Stock-in-Trade	20	(0.22)	9.23
	Direct Expenses	21	1,404.06	1,657.16
	Employee Benefit Expense	22	594.84	556.86
	Finance Cost	23	265.40	319.54
	Depreciation and Amortisation Expenses		290.01	260.63
	Other Expenses	24	574.39	211.98
	<b>Total Expenses</b>		<b>3,702.23</b>	<b>3,657.84</b>
V	<b>Profit Before Exceptional and Extraordinary Items and Tax (III - IV)</b>		<b>283.92</b>	<b>411.39</b>
VI	Exceptional Items		-	-
VII	<b>Profit Before Extraordinary Items and Tax (V - IV)</b>		<b>283.92</b>	<b>411.39</b>
VIII	Extraordinary Items		-	-
IX	<b>Profit Before Tax (VII - VIII)</b>		<b>283.92</b>	<b>411.39</b>
X	Tax expense:			
	(1) Mat Provision for the year		47.39	68.67
	Less :- Mat Credit Entitlement		-	(68.67)
XI	<b>Profit / (Loss) from the Period from Continuing Operations (IX-X)</b>		<b>236.52</b>	<b>411.39</b>
XII	Earning per Equity Share:	25		
	(1) Basic		1.12	2.29
	(2) Diluted		1.12	2.29
	<b>SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PARTS OF ACCOUNTS</b>	26		

For and on behalf of  
**SINGHI & CO.**  
Chartered Accountants  
FRN : 302049E

**SUNIL C BOHARA**  
Partner  
M. No.103395  
UDIN:23103395BGXTMN2771

Ahmedabad, 18th January 2023

For and on behalf of the Board of Directors

**BIPIN SHAH**  
Managing Director  
Din No:- 00934108

**SHREYARTHI BIPIN SHAH**  
Director  
Din No :- 02253942

**LOKESH KHANDELWAL**  
CFO

**MAYANK AGARWAL**  
Company Seceratry

Ahmedabad, 18th January 2023

# AASHKA HOSPITALS LIMITED

BETWEEN SARGASAN & RELIANCE CROSS ROAD, SARGASAN, GANDHINAGAR-382421  
CIN :- L85110GJ2012PLC072647

## CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH 2022

(₹ in Lac, except for share data and if otherwise stated)

Particulars	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
	₹	₹
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit After Taxes & Extraordinary Items	236.52	411.39
Adjustments for :		
Provision For Mat	47.39	68.67
Depreciation	290.01	260.63
Interest & Financial Charges Paid	265.40	319.54
	<b>839.32</b>	<b>1,060.23</b>
Less : Non Operating Incomes	-	-
<b>Operating Profit Before Working Capital Changes</b>	<b>839.32</b>	<b>1,060.23</b>
Adjustments for :		
Increase/Decrease In Inventories	(0.22)	9.23
Increase/Decrease In Sundry Debtors	(50.26)	(56.67)
Increase/Decrease In Other Non Current Assets	(6,634.02)	(9.85)
Increase/Decrease In Loans & Advances	0.37	12.70
Increase/Decrease In Other Current Assets	(8.44)	(65.83)
Increase/Decrease In Long Term Provision	8.28	(0.44)
Increase/Decrease In Sundry Creditors	(270.79)	191.70
Increase/Decrease In Other Current Liabilities	(100.19)	331.60
<b>Cash Generated From Operations</b>	<b>(6,215.96)</b>	<b>1,472.66</b>
<b>Net Income Tax Paid / (Net of Refunds)</b>	<b>47.39</b>	<b>22.51</b>
<b>NET CASH FLOW FROM OPERATING ACTIVITIES (A)</b>	<b>(6,263.35)</b>	<b>1,450.15</b>
<b>B. CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	(186.80)	(797.70)
Sale of Fixed Assets	-	-
<b>NET CASH FLOW FROM INVESTING ACTIVITIES (B)</b>	<b>(186.80)</b>	<b>(797.70)</b>
<b>C. CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds From Share Capital	536.80	9.45
Proceeds From Security Premium	5,958.48	85.05
Proceeds From Long Term Borrowings	(338.76)	(522.87)
Proceeds From Working Capital Limits	373.28	(48.64)
Proceeds From Long Term Liabilities	-	-
Interest & Financial Charges	(265.40)	(319.54)
<b>NET CASH FLOW FROM FINANCING ACTIVITIES ( C)</b>	<b>6,264.41</b>	<b>(796.55)</b>
<b>Net Increase/Decrease in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(185.75)</b>	<b>(144.10)</b>
Cash & Cash Equivalents at the beginning of the year	292.66	436.76
<b>Cash &amp; Cash Equivalents at the end of the year</b>	<b>106.90</b>	<b>292.66</b>

**Notes:**

1. Cash flow prepared has been prepared as per Indirect Method permitted in Accounting Standard 3 - Cash Flow Statement

2. Closing cash and cash equivalent comprises of

Balance in Current Account	45.85	0.27
Fixed Deposit	0.00	0.00
Cash in hand	61.05	292.39
	<b>106.90</b>	<b>292.66</b>

As per our report of even date attached

**For and on behalf of**  
**SINGHI & CO.**  
Chartered Accountants  
FRN : 302049E

**For and on behalf of the Board of Directors**

**BIPIN SHAH**  
Managing Director  
Din No:- 00934108

**SHREYARTHI BIPIN SHAH**  
Director  
Din No :- 02253942

**SUNIL C BOHARA**  
Partner  
M. No.103395  
UDIN:23103395BGXTMN2771

**LOKESH KHANDELWAL**  
CFO

**MAYANK AGARWAL**  
Company Seceratry

Ahmedabad, 18th January 2023

Ahmedabad, 18th January 2023

**NOTES FORMING PARTS OF THE FINANCIAL STATEMENT AS AT 31ST MARCH 2022**

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at 31st March 2022	As at 31st March 2021
		₹	₹
1	<b>Share Capital</b>		
	<b>Authorised Share Capital :</b>		
	<b>Equity Share Capital</b>	2,500.00	1,800.00
	2,50,00,000 Equity Shares of Rs. 10/- each ( Last year : 1,80,00,000 Equity Shares of Rs 10/- each)		
		<b>2,500.00</b>	<b>1,800.00</b>
<b>Issued, Subscribed &amp; Paid Share Capital</b>			
<b>Issued Share Capital :-</b>			
2,34,00,000 Equity Shares of Rs. 10/- each ( Last Year: 1,80,00,000 Equity Shares of Rs. 10/- each Fully Paid Up)	2,340.00	1,800.00	
	2,340.00	1,800.00	
<b>Suscribed &amp; Paid Share Capital</b>			
2,33,68,000 Equity Shares of Rs. 10/- each ( Last Year: 1,80,00,000 Equity Shares of Rs. 10/- each Fully Paid Up)	2,336.80	1,800.00	
<b>Total</b>	<b>2,336.80</b>	<b>1,800.00</b>	

**Note :-**

The company has only one class of equity shares, having par value of Rs. 10/- per share. Each holder of equity share is entitled for one vote per share and have a right to receive dividend as recommended by the board of directors subject to the necessary approval from the shareholders. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company after distributing of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. The board of directors have recommended dividend of Rs. Nil per share.



The Company had made an Initial Public Offer (IPO) for 84,00,000 equity shares of Rs. 10 each, comprising of 54,00,000 fresh issue of equity shares by the Company and 30,00,000 equity shares offered for sale by selling share holders. The equity shares were issued at a price of Rs. 121 per share (including premium of Rs.111 per share). Out of the total proceeds from the IPO of Rs. 10164.00 Lakhs, the Company was entitled for Rs. 6534.00 Lakhs (inclusive of premium) from the fresh issue of 54,00,000 equity shares. Fresh equity shares were allotted by the Company on 31st August, 2021 and the shares of the Company were listed on the stock exchanges on 1st September, 2021. The company did not received subscription money for 32000 shares and hence allotment of those shares had not been done by the company.

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at 31st March 2022	As at 31st March 2021
<b>1(A)</b>	<b>Reconciliation of the number of Equity Shares Outstanding at the beginning &amp; at the end of year.</b>		
	Shares outstanding at the beginning of the year	1,80,00,000	1,80,00,000
	Add : Shares issued and subscribed during the year (5400000-32000)	53,68,000	-
	<b>Shares outstanding at the end of the year</b>	<b>2,33,68,000</b>	<b>1,80,00,000</b>

Note No.	Particulars	As at 31st March 2022	As at 31st March 2021
<b>1(B)</b>	<b>Details of Shareholders Holding more than 5% of Shares</b>		
	Bipin D Shah	1,16,14,400	1,28,46,000
	Aashka Hospitality Private Limited	27,25,500	27,25,500
	Other	90,28,100	24,28,500
	<b>Number of Shares</b>	<b>2,33,68,000</b>	<b>1,80,00,000</b>

### Shareholding of Promoters

Note No.	Particulars	No. of Shares	% of total Shares	As at 31st March 2022
				% Change during the year
1(C) i	<b>Share held by the Promoter at the end of the year</b>			
	<b>Name of Promoters</b>			
	Bipinchandra Dineshbhai Shah	1,16,14,400	49.70%	21.66%
	Thakker Parag Rameshchandra	100	0.00%	2.78%
	Aashka Hospitality Pvt Ltd	27,25,500	11.66%	3.48%
	<b>Number of Shares</b>	<b>1,43,40,000</b>	<b>61.37%</b>	<b>27.93%</b>

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	No. of Shares	% of total Shares	As at 31st March 2021
				% Change during the year
1(C) i	<b>Share held by the Promoter at the end of the year</b>			
	<b>Name of Promoters</b>			
	Bipinchandra Dineshbhai Shah	1,28,46,000	71.37%	0.00%
	Thakker Parag Rameshchandra	5,01,000	2.78%	0.00%
	Aashka Hospitality Pvt Ltd	27,25,500	15.14%	0.00%
	<b>Number of Shares</b>	<b>1,60,72,500</b>	<b>89.29%</b>	<b>0.00%</b>

**NOTES FORMING PARTS OF THE FINANCIAL STATEMENT AS AT 31ST MARCH 2022**

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>2</b>	<b>Reserves and Surplus</b>		
	<b>Security Premium</b>		
	Opening Balance	1,800.00	1,714.95
	Add:- Security Premium received During the Year	5,958.48	85.05
		<b>7,758.48</b>	<b>1,800.00</b>
	<b>Surplus from profit and loss account</b>		
	Opening Balance	(675.38)	(1,086.77)
	Profit/loss during the year	236.52	411.39
		<b>(438.85)</b>	<b>(675.38)</b>
	<b>Total</b>	<b>7,319.63</b>	<b>1,124.62</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>3</b>	<b>Long-Term Borrowings</b>		
<b>a</b>	<b>Secured</b>		
i	Term Loan with Bank of India -1	495.92	1,387.54
ii	Term Loan with Bank of India -2	621.36	-
iv	FITL with Bank of India	-	6.70
v	Term Loan with SREI Equipment Finance Ltd	39.63	130.45
vi	Term Loan against Residential Property from Bank of India	487.32	490.09
		-	-
<b>b</b>	<b>Unsecured</b>		
i	From Directors	9.83	1.34
ii	From Selling Share Holders	23.31	-
	<b>Total</b>	<b>1,677.37</b>	<b>2,016.12</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>4</b>	<b>Other Long Term Liabilities</b>		
i	Security Deposit from Employee	0.40	0.40
ii	Security Deposit for Lab	50.00	50.00
	<b>Total</b>	<b>50.40</b>	<b>50.40</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>5</b>	<b>Long Term Provisions</b>		
<b>a</b>	<b>Provision for Employee Benefits</b>		
i	Provision For Gratuity	21.38	13.10
	<b>Total</b>	<b>21.38</b>	<b>13.10</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>6</b>	<b>Short Term Borrowings</b>		
<b>a</b>	<b>Loan Repayable on demand</b>		
i	Cash Credit From Bank of India -( CC A/c No.79)	249.98	96.34
ii	Cash Credit From Bank of India -( CC A/c No 112)	300.00	-
iii	Cash Credit From Bank of India -( CC A/c No 109)	49.90	-
iv	<b>From Inter Corporate Deposit</b>		
	Harsh Organochem India Pvt Ltd	-	55.00
		-	-
v	<b>Current Maturity for Long term borrowings</b>	544.06	619.32
	<b>Total</b>	<b>1,143.94</b>	<b>770.66</b>

**NOTES FORMING PARTS OF THE FINANCIAL STATEMENT AS AT 31ST MARCH 2022**

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at 31st March 2022				
		₹	₹	₹	₹	₹
		Less than 1 Years	1 -2 Years	2 - 3 Years	More than 3 Years	Total
<b>7</b>	<b>Trade Payables</b>					
<b>i</b>	<b>Due to Micro, Small &amp; Medium Enterprise</b>					
	MSME -Trade Payables for Service & Expenses	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Service & Expenses	-	-	-	-	-
	MSME Trade Payables for Canteen	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Canteen	-	-	-	-	-
	MSME Trade Payables for Pharmacy	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Pharmacy	-	-	-	-	-
	MSME Trade Payables for Capital Goods	-	-	-	-	-
	MSME Disputed Dues - Tarde Capital Goods	-	-	-	-	-
<b>ii</b>	<b>Due to Creditor other than Micro ,Small &amp; Medium Enterprise</b>					
	Trade Payables for Service & Expenses	122.02	0.12	(12.00)	(3.90)	106.24
	Disputed Dues - Tarde Payable for Service & Expenses	-	-	-	-	-
	Trade Payables for Canteen	2.00	-	-	-	2.00
	Disputed Dues - Tarde Payable for Canteen	-	-	-	-	-
	Trade Payables for Pharmacy	48.43	1.10	-	-	49.53
	Disputed Dues - Tarde Payable for Pharmacy	-	-	-	-	-
	Trade Payables for Capital Goods	1.10	-	-	-	1.10
	Disputed Dues - Tarde Capital Goods	-	-	-	-	-
	<b>Total</b>	<b>173.55</b>	<b>1.22</b>	<b>(12.00)</b>	<b>(3.90)</b>	<b>158.87</b>

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at 31st March 2021				
		₹	₹	₹	₹	₹
		Less than 1 Years	1 -2 Years	2 - 3 Years	More than 3 Years	Total
<b>7</b>	<b>Trade Payables</b>					
<b>i</b>	<b>Due to Micro, Small &amp; Medium Enterprise</b>					
	MSME -Trade Payables for Service & Expenses	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Service & Expenses	-	-	-	-	-
	MSME Trade Payables for Capital Goods	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Capital Goods	-	-	-	-	-
	MSME Trade Payables for Canteen	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Canteen	-	-	-	-	-
	MSME Trade Payables for Pahrmary	-	-	-	-	-
	MSME Disputed Dues - Tarde Payable for Pharmacy	-	-	-	-	-
		-	-	-	-	-
<b>ii</b>	<b>Due to Creditor other than Micro ,Small &amp; Medium Enterprise</b>					
	Trade Payables for Service & Expenses	336.80	(17.92)	0.04	2.24	321.15
	Disputed Dues - Tarde Payable for Service & Expenses	-	-	-	-	-
	Trade Payables for Capital Goods	8.82	-	3.51	5.98	18.31
	Disputed Dues - Tarde Payable for Capital Goods	-	-	-	-	-
	Trade Payables for Canteen	2.88	-	-	-	2.88
	Disputed Dues - Tarde Payable for Canteen	-	-	-	-	-
	Trade Payables for Pahrmary	86.59	0.47	0.22	0.05	87.33
	Disputed Dues - Tarde Payable for Pharmacy	-	-	-	-	-
		-	-	-	-	-
	<b>Total</b>	<b>435.08</b>	<b>(17.45)</b>	<b>3.77</b>	<b>8.27</b>	<b>429.67</b>

**AASHKA HOSPITALS LIMITED**

**(CIN:- U85110GJ2012PTC072647)**

Regd Office : ., B/W SARGASAN & RELIANCE CROSS ROAD, SARGASAN, GANDHINAGAR-382421, GUJARAT

Contact No: 79-25471562, Email: pyramidassociate@gmail.com

**PROPERTY, PLANT AND EQUIPMENT**

(Amount in Rs.)

**Note No : 27**

Particulars	GROSS BLOCK				DEPRECIATION / AMORTIZATION					NET BLOCK	
	As at April 1,2021	Addition during the year	Ded/Adj during the year	As at March 31,2022	Upto March 31, 2021	For the year	Ded/Adj during the year	Effect on Deprn as per Co. Act,2013	Upto March 31, 2022	As at March 31,2022	As at March 31,2021
TANGIBLE ASSETS											
PLANT AND MACHINERY	135032597	7443506	0	142476103	44383001	8857961	0	0	53240962	89235141	90649596
FURNITURE AND FITTINGS	24844385	742551	0	25586936	12883540	2424526	0	0	15308066	10278870	11960845
PLANT AND MACHINERY	46041076.66	1768144	0	47809220.66	15294360	2837188	0	0	18131548	29677672.66	30746716.66
PLANT AND MACHINERY	1991012	0	0	1991012	981998	96524	0	0	1078522	912490	1009014
PLANT AND MACHINERY	1280573	0	0	1280573	632458	62019	0	0	694477	586096	648115
PLANT AND MACHINERY	45059375.96	8673950	0	53733325.96	15483132	3203545	0	0	18686677	35046648.96	29576243.96
PLANT AND MACHINERY	1111885	0	0	1111885	347699	70437	0	0	418136	693749	764186
MOTOR VEHICLES	3280545	0	0	3280545	1222546	191330	0	0	1413876	1866669	2057999
COMPUTERS AND DATA PROCESSING UNITS	6903559	25842	0	6929401	5903843	497059	0	0	6400902	528499	999716
BUILDINGS	266127405	0	0	266127405	46942285	8428274	0	0	55370559	210756846	219185120
OFFICE EQUIPMENT	1598525	26500	0	1625025	529432	104822	0	0	634254	990771	1069093
LAND	36471878	0	0	36471878	0	0	0	0	0	36471878	36471878
PLANT AND MACHINERY	390000	0	0	390000	105503	24643	0	0	130146	259854	284497
BUILDINGS	69560600	0	0	69560600	60349	2202752	0	0	2263101	67297499	69500251
Total :	639693416.62	18680493	0.00	658373909.62	144770146	29001080	0.00	0.00	173771226	484602683.62	494923270.62
Previous Year Total	559923178	79770238.62	0	639693416.62	118707259	26062887	0	0.00	144770146	494923270.62	441215919

**NOTES FORMING PARTS OF THE FINANCIAL STATEMENT AS AT 31ST MARCH 2022**

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>8</b>	<b>Other Current Liabilities</b>		
i	Other Statutory Liabilities	62.67	204.30
	<b>Total</b>	<b>62.67</b>	<b>204.30</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>9</b>	<b>Short-Term Provisions</b>		
i	Provision for Employee Benefits	32.35	28.09
ii	Provision for Expenses & Others	108.35	71.17
	<b>Total</b>	<b>140.70</b>	<b>99.26</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>10</b>	<b>Property , Plant &amp; Equipment &amp; Intangible assets</b>		
i	Land/ Building/ Plant & Equipment/ Furniture & fixtures/ Vehicles/ Office Equipment/Others (individually)		
	Opening Balance	6,396.93	5,599.23
	Add: Acquisition through business combination	-	-
	Other Adjustments	186.80	797.70
	Sub total	6,583.74	6,396.93
	Less: Disposals	-	-
	<b>Gross Block at year end (a)</b>	<b>6,583.74</b>	<b>6,396.93</b>
	Less: Depreciation		
	Opening Depreciation	1,447.70	1,187.07
	Depreciation for the year	290.01	260.63
	Other Adjustments	-	-
	Effect on Depreciation As per Co. Act, 2013	-	-
	<b>Total Accumulated Depreciation (b)</b>	<b>1,737.71</b>	<b>1,447.70</b>
	Net Carrying Value (a) - (b)	4,846.03	4,949.23
	<b>Total</b>	<b>4,846.03</b>	<b>4,949.23</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>11</b>	<b>Other Non Current Assets</b>		
i	Security Deposits	121.33	36.35
ii	Loang Term Loan & Advance	6,704.04	155.00
	<b>Total</b>	<b>6,825.37</b>	<b>191.35</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>12</b>	<b>Inventories</b>		
i	Closing Stock in Hand	54.52	54.30
	<b>Total</b>	<b>54.52</b>	<b>54.30</b>

**NOTES FORMING PARTS OF THE FINANCIAL STATEMENT AS AT 31ST MARCH 2022**

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at 31st March 2022					
		₹	₹	₹	₹	₹	₹
		Less than 6 months	6 months - 1 years	1 - 2 years	2 - 3 years	More than 3 years	Total
<b>13</b>	<b>Trade Receivables</b>						
	Undisputed Trade Receivables- Considered Goods	360.01	161.61	235.37	23.60	1.28	<b>781.88</b>
	Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
	Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
	Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
	<b>Total</b>	<b>360.01</b>	<b>161.61</b>	<b>235.37</b>	<b>23.60</b>	<b>1.28</b>	<b>781.88</b>

Note No.	Particulars	As at 31st March 2021					
		₹	₹	₹	₹	₹	₹
		Less than 6 months	6 months - 1 years	1 - 2 years	2 - 3 years	More than 3 years	Total
<b>13</b>	<b>Trade Receivables</b>						
	Undisputed Trade Receivables- Considered Goods	401.98	124.96	73.27	5.41	126.00	731.62
	Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
	Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
	Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
	<b>Total</b>	<b>401.98</b>	<b>124.96</b>	<b>73.27</b>	<b>5.41</b>	<b>126.00</b>	<b>731.62</b>

	As at 31st March 2022	As at 31st March 2021
	₹	₹
<b>UNSECURED</b>		
Considered Good	781.88	731.62
Considered Doubtful	-	-
Less: Provision for Doubtful Trade Receivables	-	-
Others (Considered Good)		
<b>TOTAL UNSECURED (A)</b>	<b>781.88</b>	<b>731.62</b>
<b>SECURED</b>		
Considered Good	-	-
Considered Doubtful	-	-
Less: Provision for Doubtful Trade Receivables	-	-
Others (Considered Good)	-	-
<b>TOTAL SECURED (B)</b>	<b>-</b>	<b>-</b>
<b>TOTAL TRADE RECEIVABLES (A + B)</b>	<b>781.88</b>	<b>731.62</b>



**NOTES FORMING PARTS OF THE FINANCIAL STATEMENT AS AT 31ST MARCH 2022**

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>14</b>	<b>Cash and Cash Equivalents</b>		
i	Balances with Schedule Bank in Current Account	45.85	0.27
ii	Cash on hand	61.05	292.39
	<b>Total</b>	<b>106.90</b>	<b>292.66</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>15</b>	<b>Short Term Loans &amp; Advances</b>		
i	Other Loans and advances		
	-Advance recoverable in cash or in kind or for value to be received		
	Advance givn to Staff /Employee	6.51	6.88
	<b>Total</b>	<b>6.51</b>	<b>6.88</b>

Note No.	Particulars	As at	As at
		31st March 2022	31st March 2021
		₹	₹
<b>16</b>	<b>Other Current Assets</b>		
i	Balance with Revenue Authorities	277.07	267.35
ii	Prepaid Expenses	13.47	14.76
	<b>Total</b>	<b>290.54</b>	<b>282.10</b>

Note No.	Particulars	For the Year Ended	For the Year Ended
		31st March 2022	31st March 2021
		₹	₹
<b>17</b>	<b>Revenue from Operations (for Companies other than a finance company)</b>		
	Canteen Sales	30.21	33.21
	IPD Income	2,870.59	3,118.02
	OPD Income	125.55	144.07
	Pharmacy Income	947.01	773.58
	<b>Total</b>	<b>3,973.36</b>	<b>4,068.88</b>

Note No.	Particulars	For the Year Ended	For the Year Ended
		31st March 2022	31st March 2021
		₹	₹
<b>18</b>	<b>Other Income</b>		
	Interest on Deposit	1.84	0.35
	Sundry Creditors write off	7.53	-
	Income from Scrap	0.13	-
	Insurance Received	3.28	-
	<b>Total</b>	<b>12.78</b>	<b>0.35</b>

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
		₹	₹
19	<b>Purchase</b> Purchases	573.75	642.44
	<b>Total</b>	<b>573.75</b>	<b>642.44</b>

Note No.	Particulars	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
		₹	₹
20	<b>Change In Inventories</b> Closing Stock of Pharmacy & Canteen Materials Opening Stock of Pharmacy & Canteen Materials	54.52 54.30	54.30 63.53
	<b>Total</b>	<b>(0.22)</b>	<b>9.23</b>

Note No.	Particulars	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
		₹	₹
21	<b>Direct Expenses</b> Blood Testing Charges Consultancy Expenses Dialysis Charges Electricity Exp Hospital Other Exp Hospital Store & Spare Exp Implant for Patient Lab Testing Fees MRI Exp Oxygen Cylinder Exp Patient ID Band Radiology Exp PPE Kit Exps Rent Expenses for COVID Staff	9.50 967.35 5.30 86.72 70.12 31.48 15.90 137.14 0.78 56.01 0.06 2.26 21.43 -	14.62 1,084.47 3.66 84.28 53.11 29.76 16.40 227.62 0.39 66.95 0.05 2.20 67.59 6.07
	<b>Total</b>	<b>1,404.06</b>	<b>1,657.16</b>

Note No.	Particulars	For the Year Ended 31st March 2022	For the Year Ended 31st March 2021
		₹	₹
22	<b>Employee Benefit Expenses</b> Salary Exp Director Remuneration Director Consulting Charges Bonus Exp Contribution to Fund Gratuity Exps Staff Welfare Exp Labour Welfare Fund Exps Leave Encashment Exps	430.07 120.00 - 8.99 26.81 5.11 2.42 0.32 1.12	424.37 84.00 3.50 8.49 25.88 3.16 7.45 - -
	<b>Total</b>	<b>594.84</b>	<b>556.86</b>

(₹ in Lac, except for share data and if otherwise stated)

Note No.	Particulars	For the Year Ended	For the Year Ended
		31st March 2022	31st March 2021
		₹	₹
<b>23</b>	<b>Financial Cost</b>		
	Bank Interest	224.68	276.70
	Interest on NBFC Loan	21.04	26.69
	Interest on Unsecured Loan	-	0.44
	Bank Loan Processing & Other Charges	19.68	15.71
	<b>Total</b>	<b>265.40</b>	<b>319.54</b>

Note No.	Particulars	For the Year Ended	For the Year Ended
		31st March 2022	31st March 2021
		₹	₹
<b>24</b>	<b>Other Expenses</b>		
	Advertisement Expenses	-	6.48
	Audit Fees	10.00	5.00
	ASBA Bidding Charges	3.75	-
	Association Fees	0.06	-
	Business Promotion Exps	4.70	-
	CSDL & NSDL Annual Fees	1.32	-
	Computer Expenses	2.12	1.89
	Conveyance & Petrol Expenses	7.98	9.55
	Donation	-	-
	IPO Exps	277.34	-
	Entertainment Expenses	1.92	1.96
	EPF Interest & Damage Charges	4.63	-
	Insurance Expenses	9.25	9.21
	Interest on Duties & Taxes	25.97	5.21
	Legal & Liasoning Expenses	14.71	1.57
	Mehsul Tax & Guda Tax	1.35	3.59
	Misc Expenses	0.03	0.15
	NABH Expenses	3.84	1.95
	Dematerialization Charges	-	0.93
	Office Expenses	1.62	0.80
	Postage & Courier Expenses	0.44	0.25
	Printing & Stationery Expenses	13.18	12.34
	Prior Period Exps	9.05	-
	Bad Debts	19.51	4.41
	Professional Fees	32.54	3.54
	Rent Expenses	7.72	49.44
	Kasar & Vatav	2.64	4.35
	Repair & Maintenance Expenses	76.75	62.98
	ROC Expenses	6.96	0.10
	Security Guard Charges	24.01	22.17
	Telephone & Internet Expenses	2.54	2.92
	Travelling Expenses	8.47	1.18
		-	-
	<b>Total</b>	<b>574.39</b>	<b>211.98</b>

Note No.	Particulars	For the Year Ended	For the Year Ended
		31st March 2022	31st March 2021
		₹	₹
<b>25</b>	<b>Earning Per Share</b>		
	<b>Basic &amp; Diluted</b>		
	Profit After Tax available for Equity Share Holders	236.52	411.39
	No of Equity Shares outstanding	2,33,68,000	1,80,00,000
	Weighted Average No. of Equity Shares	2,11,32,559	1,79,71,521
	Earning Per Share- Basic	1.12	2.29
	Earning Per Share- Diluted	1.12	2.29

## **AASHKA HOSPITALS LIMITED**

### **NOTES FORMING PART OF THE ACCOUNTS FOR THE YEAR ENDED ON 31<sup>ST</sup> MARCH, 2022**

#### **NOTE NO. 26**

##### **COMPANY OVERVIEW**

AASHKA HOSPITALS LIMITED Company was incorporated on **9<sup>th</sup> November, 2012 under chapter IX of Companies Act, 1956**. The Address of its registered office and principal place of business are disclosed in the introduction of the Annual Report. The Principal Activities of the Company include Operation of Multi Disciplinary Private Hospital, Clinics, and Pharmacies. The Main Business of the Company is to enhance the quality of life of Patient by providing Comprehensive, High Quality Hospital Services on a cost-effective basis.

##### **A- SIGNIFICANT ACCOUNTING POLICY**

###### **1. BASIS OF PREPARATION OF FINANCIAL STATEMENTS:-**

The accounting principles and policies, recognized as appropriate for measurement and reporting of the financial performance and financial position on accrual basis except as otherwise disclosed, using historical costs (i.e., not taking in to account changing money values impact of inflation) are applied in the preparation of the financial statements and those which are considered materials to the affaires are suitably disclosed. The Financial Statements are in accordance with the requirements of the Companies Act, 2013.

###### **2. USE OF ESTIMATES:-**

The preparation of Financial Statements requires estimates and assumption to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues & expenses during the reporting period. Difference between actual results and estimates are recognized in the period in which the results are known /materialized.

###### **3. INVENTORIES:-**

Inventory comprises of Pharmacy Stock and Consumable. Pharmacy Stock is valued at the lower of Cost and net realizable value. Consumable are valued at Cost. Cost comprises purchase price and all incidental expenses incurred in bringing the inventory to its present location and condition. The Company follows the FIFO method for determining the Cost of Inventories.

###### **4. CASH & CASH EQUIVALENTS:-**

Cash comprises Cash on hand and Demand Deposits with Banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

###### **5. CASH FLOW :-**

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

## **6. EVENTS OCCURRING AFTER THE BALANCE SHEET :-**

Material events occurring after the balance sheet are considered up to the date of approval of the accounts by the board of directors. There are no substantial events having an impact on the results of the current year Balance Sheet.

## **7. PROPERTY, PLANT AND EQUIPMENT:-**

Property, Plant and Equipment are recorded at cost of acquisition with construction cost if any. They are stated at historical cost less accumulated depreciation, amortization and impairment loss, if any. Cost includes expenditures that is directly attributable to the acquisition of the items.

## **8. DEPRECIATION ON PROPERTY, PLANT AND EQUIPMENT:-**

The Company depreciates Property, Plant and Equipment over the estimated useful life on a straight-line basis from the date the assets are available for use. Freehold land is not depreciated. The estimated useful life of assets are reviewed and where appropriate are adjusted, annually.

## **9. REVENUE RECOGNITION :-**

Rendering of Services:-

Revenue primarily comprises of fees charged for inpatient and outpatient hospital services. Services include charges for accommodation, theatre, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used. Revenue is recorded and recognized during the period in which the hospital services is provide, based upon the estimated amounts due from patients and/or medical funding entities. Unbilled revenue is recorded for the services where the patients are not discharged and invoice is not raised for the service.

Revenue from hospital services to patients is recognized as revenue when the related services are rendered unless significant future uncertainties exist relating to the ultimate collection. Revenue is also recognized in relation to the services rendered to the patients who are undergoing treatment/observation on the balance sheet to the extent of services rendered. Revenue is recognized net of discounts and concessions given to the patients.

Revenue from sale of pharmacy products within hospital premises is recognized on sale of medicines and similar products to the buyer. The amount of revenue recognized is net of sales returns and exclusive of sales tax, GST and trade discounts, wherever applicable.

'Unbilled revenue' represents value of medical and healthcare services rendered in excess of amounts billed to the patients as the balance sheet date.

Interest income is recognized using the time-proportion method, based on underlying interest rates.

### **Canteen Income:-**

Add-on service of providing food and refreshment to inpatient are recognized on accrual basis and to their relatives are recognized on cash basis.

#### **10. BORROWING COST:-**

Borrowing costs that are directly attributable to the acquisition, construction or production of fixed assets are considered as part of the cost of that asset till the date of the acquisition. Other borrowing costs are recognized as an expense in the period in which they are incurred.

#### **11. EARNING PER SHARE:-**

Basic earning per share is computed by dividing the profit/ (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earning per share is computed by dividing the profit/(loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earning per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potentially equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits/reverse share splits and bonus shares, as appropriate.

#### **12. TAXES ON INCOME :-**

Tax Expenses for the year, i.e. Current Tax is included in determining the net profit for the year. A provision is made for the current tax liability computed in accordance with relevant tax rates and tax laws.

Minimum Alternative tax ( MAT ) paid in accordance with the tax laws, which gives rise to future economic benefits in the form of adjustment of future income tax liability, is considered as an asset if there is convincing evidence that the Group will pay normal tax after the tax holiday period. Accordingly, MAT is recognized as an asset in the balance sheet when it is probable that the future economic benefit associated with it will flow to the Group and the asset can be measured reliably.

Deferred Taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier year. Deferred Tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date.

#### **13. DEFERRED TAX-ASSET/LIABILITY:-**

As per the Prudence concept, Deferred Tax Assets are recognized and carried forward only to the extent that there is reasonable certainty of their realization.

However considering past record of the Company and by making realistic estimates of profit for the future, its prudence we are not recognizing Differed Assets as on date.

However the same will be recognized as an when there is realistic estimates of the Profit.

#### 14. IMPAIRMENT OF ASSETS:-

The Management periodically assesses, using external and internal sources whether there is an indication that an assets may be impaired If an asset is impaired, the Company recognizes impairment loss as the excess of carrying amount of the assets over recoverable amount.

#### B- NOTES TO ACCOUNTS:-

1. The notes referred to in the Balance Sheet and Profit and Loss Account forms an integral part of the accounts.
2. Balances of “Depositors”, “Trade Payables”, “Trade Receivables”, “Secured Loans”, “Unsecured Loans” and “Loans and Advances” are subject to confirmations and reconciliations.
3. In the opinion of the Board of Directors, the current assets, loans and advances are approximately of the value stated, if realized in the ordinary course of business.
4. Previous year figures have been regrouped / rearranged wherever it founds necessary.

#### 5. MICRO, SMALL AND MEDIUM SCALE BUSINESS ENTITIES:

A sum of NIL is payable to MSME payables as at 31<sup>st</sup> March, 2022 (PY NIL). There is no Micro and Small Enterprises Payable, to whom the Company owes dues, which is not outstanding for more than 45 days during the year. This information as required to be disclosed under the Micro, Small and Medium Enterprises Development Act, 2006 has been determined to the extent such parties have been identified on the basis of information available with the Company and provided to us.

Sl. No.	Particulars	As at 31st March 2022	As at 31st March 2021
		₹	₹
i	The Principal amount and the Interest due thereon remaining unpaid to any supplier at the end of each financial year. (Micro Enterprise)		
	-Principal Amount	-	-
	-Interest Amount	-	-
ii	The amount of interest paid by the buyer in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year.	-	-

iii	The amount of interest due and payable for the period of delay in making payment but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006	-	-
iv	The amount of interest accrued and remaining unpaid at the end of each accounting year		
v	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under Section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-	-

6. Employees whose remuneration in aggregate was not less than ₹ 1,02,00,000/- per annum and part of the employees whose remuneration was not less than ₹ 8,50,000/- per month is Nil.

7. The Details of Payment to Statutory auditors are as under. (₹ in Lakhs)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2022	For the Year Ended 31 <sup>st</sup> March, 2021
Audit Fees	7.50/-	3.50/-
Tax Audit Fees	2.00/-	1.00/-
Certification Charges	0.50/-	0.50/-
<b>Total...</b>	<b>10.00/-</b>	<b>5.00/-</b>

8. Value of Imports calculates on CIF Basis. (₹ in Lakhs)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2022	For the Year Ended 31 <sup>st</sup> March, 2021
Value of Import As Per CIF Basis	NIL	NIL

9. Expenditure in Foreign Currency (₹ in Lakhs)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2022	For the Year Ended 31 <sup>st</sup> March, 2021
Expenditure in Foreign Currency	NIL	NIL

10. Earning in Foreign Currency in FOB (₹ in Lakhs)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2022	For the Year Ended 31 <sup>st</sup> March, 2021
Earning in Foreign Currency	NIL	NIL



**11. EARNING PER EQUITY SHARE**

Basics &amp; Diluted

(₹ in Lakhs)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2022	For the Year Ended 31 <sup>st</sup> March, 2021
Profit after Tax available for Equity Shareholders	236.52	411.39
No. of Equity Share of ₹ 10 each at the Beginning	1,80,00,000	1,80,00,000
No. of Equity Shares of ₹ 10 each at the end of the period	2,33,68,000	1,80,00,000
Weight an Average of Share	2,11,32,559	1,79,71,521
Earning Per Share – Basic	1.12	2.29
Earning Per Share – Diluted	1.12	2.29

EPS is calculated as per Accounting Standard-20 considering the splitting of Equity Shares and accordingly EPS is adjusted for the comparative previous year presented.

**12. Related Party Disclosure:-**

<b>Subsidiaries</b>	None
<b>Associates</b>	None
<b>Key Management Personal &amp; their Relatives</b>	Bipinchandra Shah
	Parag Rameshchandra Thakkar
	Shreyarthi Bipin Shah
	Hiteskumar Ramanlal Shah
	Aashka Shah
<b>Enterprise in which Key Management Personal, and their Relatives have significant influence</b>	Pyramid Associates
	Pryamid Worldwide Pvt Ltd
	Aashka Hospitality Pvt Ltd

**(A) Transactions with Related Parties for the year ended March 31, 2022**

(₹ in Lakhs)

Particulars	2021-22	2020-21
Unsecured Loan taken	1995.39/-	553.79/-
Unsecured Loan Repayment	1986.90/-	853.74/-
Director Remuneration	120.00/-	84.00/-
Salary Exps	12.00/-	9.00/-
Advance given for Purchase of Property	2870.42/-	650.00/-
Director Consulting Charges	--	3.50/-

**(B) Balance as at March 31,2022**

(₹ in Lakhs)

Particulars	2021-22	2020-21
Unsecured Loan	9.83/-	1.34/-
Creditor for Exps	--	7.43/-
Director's Remuneration Payable	3.16/-	--
Advance given for Purchase of Property	2870.42/-	--

### 13. SECURED LOANS:

#### a) Following are the secured loans obtained by the company;

1. Cash Credit Limit from **Bank of India. Ellisbridge Branch**
2. Term Loan Facilities from **Bank of India. Ellisbridge Branch**
3. Working Capital Term Loan (WCTL) from **Bank of India. Ellisbridge Branch**
4. Term Loan Facility from **SREI Equipment Finance Ltd.**
5. Housing Loan from **Bank of India. Ellisbridge Branch**

The above Facilities are secured by the following security;

#### 1. Cash Credit Facility , Term Loan I & WCTL From Bank of India is secured by

##### →Primary Security:-

- Hypothecation of Plant & Machineries.( Assets ID :- 200014852345),
- Hypothecation of Stock & Book Debts.
- Equitable Mortgage of Hospitals Land & Building Situated at Sy No. 168/1 of 2005 Sq. Mts and Sy No. 168/2, of 1055 Sq. Mts of total admeasuring of 3060 Sq. Mts , Village-Sargasan, Tehsil Gandhinagar in the name of Aashka Hospital Ltd.

##### →Collateral Security:-

Equitable Mortgage of Plot no NA Land S. No. 404, 405, 406, 407, 408 , 409, 412, 413, 414, at Dharmoda , Tal Chanasma , Dist Patan, Gujarat admeasuring 66155 Sq. Mts Owned by Mr. Rameshbhai Maganbhai Desai & Mr. Bipin Dineshchandra Shah (Asset ID :- 200006252445).

Equitable Mortgage of Open Plot Sr. No. of NA Land, Survey No. 84,98,144,148,155,160,165, 169,196 & 208. Block No.531,542, and 543 at Dharisana, Taluka Degham, Dist Gandhinagar owned by Shri Bipin Shah, Shri Haresh Shah & Shri Girish Shah. (Asset ID :- 200006252445).

Equitable of Open Plot at Sanj Upvan Survey No. of NA Land Survey No. 6,8,11,12,12/A,46,47,50,52,54,57,69,79,83,95,105,106,192,193,197,200,204 Block No. 531 at Dharisana, Taluka- Degham Dist Gandhinagar owned by Shri Bipin Shah, Shri Haresh Shah and Shri Girish Shah.

Equitable of Open Plot NA Land Sanj Upvan Plot No. 107, 108,109,112,112/A,114 to 116, 124,128, 131 to 133, 136, 137, 140, 141, 149, 153 & 194 of Block No. 531 & 543 at Dharisana, Taluka- Degham Dist Gandhinagar owned by Shri Bipin Shah, Shri Haresh Shah and Shri Girish Shah.

#### 2. Term Loans from SREI Equipment Finance Ltd

##### →Primary Security:-

Hypothecation of Cath Lab Equipment of the Company.

##### →Collateral Security:-

Registered Mortgage of Commercial Land (Plot No 30 to 45) admeasuring 11481 sq yards located at Mouje – Dharisana , Taluka – Dahegam, Gandhinagar District &

Owned by Mr. Bipin Shah and his brothers Mr. Harish Shah and Dinesh Shah

### 3. Term Loan against residential property of Director from Bank of India

Equitable Mortgage of Property situated at, Bunglow No. 39, Chaitnyanagar Society ,  
Opp. Saviour Hospital, Stadium Road, Navrangpura, Ahmedabad, Gujarat

The repayment terms of the above loans are as under:-

Sr. No.	Nature of Loans	Repayment Terms
1.	Cash Credit for Bank of India	Repayable on Demand
2.	Term Loan 1 from Bank of India	In 122 Equated monthly Installment each of Rs. 40,00,000/-.
4.	WCDL ( GECL) form Bank of India	In 36 Equated monthly installment each of Rs. 19,34,807/- after initial moratorium of 24 month ( Interest to be serviced during moratorium period as and when charged)
5.	Term Loan against Residential property of Director from Bank of India.	In 300 Equated monthly Installment each of Rs. 3,54,277/-.
6.	Term Loan Facility from SREI Equipment Finance Limited	In 48 Equated monthly Installment each of Rs. 6,70,721/-.

### 14. Contingent Liabilities & Commitments ( to the extent not provided for ):- (₹ in Lakhs)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2022	For the Year Ended 31 <sup>st</sup> March, 2021
<b>Contingent Liabilities</b>		
Claim against the Company not acknowledged as debt	Nil	Nil
Guarantee	Nil	Nil
Other money for which the Company is contingently liable	Nil	Nil
<b>Commitments</b>		
Estimated amount contracts remaining to be executed on capital account and not provided for	Nil	Nil
Uncalled liability on shares and other Investments partly paid	Nil	Nil
Other Commitments	Nil	Nil

### 15. Ratio Disclosure :-

Sr.No.	Particulars	Ratio for the F Y 2021-22	Ratio for the F Y 2020-21
1	Current Ratio	0.82	1.01
2	Debt- Equity Ratio	0.34	1.23

3	Debt Service Coverage Ratio	1.85	1.07
4	Return on Equity Ratio	0.04	0.15
5	Inventory Turnover Ratio	73.02	69.07
6	Trade Receivables Turnover Ratio	5.25	5.79
7	Trade Payable Turnover Ratio	1.95	1.92
8	Net Capital Turnover Ratio	(9.88)	13.53
9	Net Profit Ratio	5.95	10.11
10	Return on Capital Employed	4.67	14.48
11	Return on Investment	2.51	16.37

**For and on behalf of  
SINGHI & CO.  
Chartered Accountants  
FRN : 302049E**

**For and on behalf of the Board of Directors**

**BIPIN SHAH  
Managing Director  
Din No:- 00934108**

**SHREYARTHI BIPIN  
SHAH  
Director  
Din No :- 02253942**

**SUNIL C BOHARA  
Partner  
M. No.103395  
UDIN: 23103395BGXTMN2771**

**Ahmedabad, 18<sup>th</sup> January 2023**

**Ahmedabad, 18<sup>th</sup> January 2023**

**ATTENDANCE SLIP****AASHKA HOSPITALS LIMITED**

**Reg. Off.:** Between Sargasan and Reliance Cross Roads, Sargasan, Gandhinagar – 382421  
**CIN:** L85110GJ2012PLC072647 | **E-Mail:** cs@aashkahospitals.in | **Web:** www.aashkahospitals.in  
**Ph.:** +91-79-2975-0750; +91-75750-06000 / 9000 | **Emergency:** +91-75750-07707 / 98797-52777

10<sup>th</sup> Annual General Meeting to be held on Friday, April 28, 2023 at 11:30 a.m.

<b>DP. Id*</b>		Name & address of the registered shareholder
<b>Client Id*</b>		
<b>Regd. Folio No.</b>		

\* Applicable for shareholding in electronic form.

I/We certify that I/We am/are a Registered Shareholder / Proxy for the Registered Shareholder of the Company. I/We hereby record my/our presence at the Extra Ordinary General Meeting of the Company

\_\_\_\_\_  
*Signature of Member(s)/ Proxy*

**NOTE:** A member or his duly appointed Proxy willing to attend the meeting must fill-up this Admission Slip and hand over at the entrance.

✂-----Cut Here-----

**PROXY FORM****Form No MGT-11**

(Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the companies (Management and Administration) Rules, 2014)

<b>CIN</b>	L85110GJ2012PLC072647
<b>Name of Company</b>	Aashka Hospitals Limited
<b>Reg. Office Address</b>	Between Sargasan and Reliance Cross Roads, Sargasan, Gandhingar – 382421
<b>Name of the Member</b>	
<b>Registered Address</b>	
<b>E Mail Id</b>	
<b>Folio No./Client ID</b>	

I/We, being the member (s) of **Aashka Hospitals Limited** hereby appoint

Name	
Address	
E mail Id	Signature

OR FAILING HIM

Name	
Address	
E mail Id	Signature

OR FAILING HIM

Name			
Address			
E mail Id		Signature	

As my/ our Proxy to attend and vote for me/us on my/ our behalf at the 10<sup>th</sup> Annual General Meeting of the Company to be held on April 28, 2023 at 11:30 a.m. and at any adjournment thereof and respect of such resolution mentioned below:

Resolution No.	Resolution	For	Against
<b>Ordinary Business</b>			
01	To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2022 together with the Board's Report and the Auditor's Report thereon.		
02	To appoint Director in the place of Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108), who retires by rotation and being eligible, offers himself for re-appointment		
03	To appoint Mr. Umang Ashwinbhai Shah (DIN: 09735002) as an Independent Director		
04	To re-appoint Mr. Bipinchandra Dineshbhai Shah (DIN: 00934108) as Chairman and Managing Director		

Signed on this .....day of .....2023


Affix  
Revenue  
Stamp

Signature of Shareholder ..... / Signature of Proxy .....

**NOTE:**

1. The Proxy need not be a Member.
2. The Proxy Form must be deposited at the Registered Office not less than 48 hours before the scheduled time for holding the meeting.

# ROUTE MAP FOR AGM



# BOOK - POST

If undelivered please return to:  
**Aashka Hospitals Limited**  
Between Sargasan & Reliance Cross Roads,  
Sargasan, Gandhinagar - 382421  
Ph: 079-2975-0750